doc_id,sentence_id,product_a,product_a_alias,product_b,product_b_alias,sentence_text,publication_date,journal,section,sent_index,count,recency_weight,study_type,study_type_weight,combined_weight,evidence_weight,labels,matched_terms,context_rule_hits,indications,direction_type,product_a_role,product_b_role,direction_triggers,narrative_type,narrative_subtype,narrative_confidence,sentiment_label,sentiment_score,sentiment_model,sentiment_inference_ts,confidence_breakdown
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,"In a large-scale randomized controlled study of heart failure (HF), angiotensin receptor-neprilysin inhibitors (ARNI) reduced cardiovascular events compared to enalapril, but resulted in more symptomatic hypotension.",2026-01-08,,abstract,1,1,1.0,other,1.0,1.0,1.0,"['compared to', 'randomized']","{""comparative_terms"": [""compared to""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:4,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,ARNI,"Among 166 patients treated with newly prescribed renin-angiotensin system inhibitor (75.7 ± 13.4 years, 57.2% men, and ejection fraction 39 ± 17%), 114 were treated with newly prescribed ARNI (ARNI group) and 52 were treated with newly prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers but without ARNI (ACEi/ARB group).",2026-01-08,,abstract,4,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,The initial day of prescription was day 4 [2-6] for the ARNI group and day 3 [1-6] for the ACEi/ARB group.,2026-01-08,,abstract,5,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Three days after the initiation of each drug, systolic BP dropped from 132 ± 24 to 117 ± 19 mmHg (ARNI group, p < 0.001) and 131 ± 19 to 117 ± 21 mmHg (ACEi/ARB group, p < 0.001).",2026-01-08,,abstract,6,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41501364,med:pmid:41501364:sec:abstract:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,Early changes in BP after ARNI initiation were comparable with those in the ACEi/ARB group.,2026-01-08,,abstract,9,1,1.0,other,1.0,1.0,1.0,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 1.0, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 1.0, 'final_confidence': 1.0}"
med:pmid:41335448,med:pmid:41335448:sec:conclusion:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group.",2026-01-01,,conclusion,13,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,['no significant difference'],"{""comparative_terms"": [""no significant difference""], ""claim_strength_terms"": {""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],comparative,comparative_efficacy,0.6,POS,2.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:methods:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy.",2026-01-01,,methods,5,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,"['add-on therapy', 'randomized']","{""add-on therapy"": [""in addition to standard therapy""], ""study_context"": [""randomized""]}","['relationship:add-on therapy', 'study_context']",[],add_on,add_on,backbone,['add_on_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.,2026-01-01,,results,10,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).",2026-01-01,,results,11,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril.",2026-01-01,,results,12,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).",2026-01-01,,results,8,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.",2026-01-01,,results,9,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41335448,med:pmid:41335448:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.",2026-01-01,,results,0,1,0.9867947312196229,randomized controlled trial,1.6,1.5788715699513967,1.5788715699513967,"['vs', 'clinical trial', 'randomized', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""clinical trial"", ""randomized"", ""trial""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.7,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9867947312196229, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.5788715699513967, 'final_confidence': 1.5788715699513967}"
med:pmid:41455057,med:pmid:41455057:sec:abstract:sent:2,enalapril,angiotensin converting enzyme inhibitors,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation.",2025-12-27,,abstract,2,1,0.9793273044104384,review,0.9,0.8813945739693946,0.8813945739693946,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9793273044104384, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8813945739693946, 'final_confidence': 0.8813945739693946}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNI,"In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i.",2025-12-17,,results,10,1,0.9609050283063585,other,1.0,0.9609050283063585,0.9609050283063585,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9609050283063585, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9609050283063585, 'final_confidence': 0.9609050283063585}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor-neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-12-17,,results,5,1,0.9609050283063585,other,1.0,0.9609050283063585,0.9609050283063585,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9609050283063585, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9609050283063585, 'final_confidence': 0.9609050283063585}"
med:pmid:41408894,med:pmid:41408894:sec:results:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,"Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i.",2025-12-17,,results,9,1,0.9609050283063585,other,1.0,0.9609050283063585,0.9609050283063585,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.9609050283063585, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.9609050283063585, 'final_confidence': 0.9609050283063585}"
med:pmid:41379379,med:pmid:41379379:sec:abstract:sent:1,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Chronic heart failure with reduced ejection fraction (HFrEF) is a progressive syndrome associated with substantial residual morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT) - angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) [1].",2025-12-11,,abstract,1,1,0.950018423870487,review,0.9,0.8550165814834383,0.8550165814834383,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.950018423870487, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8550165814834383, 'final_confidence': 0.8550165814834383}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:10,enalapril,ACEi,sacubitril_valsartan,ARNI,"Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69]).",2025-11-17,,results,10,1,0.9076915125983672,review,0.9,0.8169223613385305,0.8169223613385305,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.6499999999999999,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9076915125983672, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8169223613385305, 'final_confidence': 0.8169223613385305}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNI,"Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals.",2025-11-17,,results,12,1,0.9076915125983672,review,0.9,0.8169223613385305,0.8169223613385305,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.6499999999999999,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9076915125983672, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8169223613385305, 'final_confidence': 0.8169223613385305}"
med:pmid:41249923,med:pmid:41249923:sec:results:sent:14,enalapril,ACEi,sacubitril_valsartan,ARNI,"In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99]).",2025-11-17,,results,14,1,0.9076915125983672,review,0.9,0.8169223613385305,0.8169223613385305,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.6499999999999999,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.9076915125983672, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.8169223613385305, 'final_confidence': 0.8169223613385305}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI/ACEI/ARB therapy was optimized in 48.4% of the subjects, with optimization rates of 37.9%, 40.2%, and 44.1% for beta-blockers, MRAs, and SGLT2is, respectively.",2025-11-11,,introduction,10,1,0.897407792400885,other,1.0,0.897407792400885,0.897407792400885,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.897407792400885, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.897407792400885, 'final_confidence': 0.897407792400885}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"However, only 38 (22.0%) patients reached the level of treatment corresponding to ""SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses ≥ 50%"".",2025-11-11,,introduction,11,1,0.897407792400885,other,1.0,0.897407792400885,0.897407792400885,['combination'],"{""combination"": [""arni/acei/arb""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.897407792400885, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.897407792400885, 'final_confidence': 0.897407792400885}"
med:pmid:41303015,med:pmid:41303015:sec:introduction:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%.",2025-11-11,,introduction,9,1,0.897407792400885,other,1.0,0.897407792400885,0.897407792400885,[],,[],[],,,,[],,,,POS,4.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.897407792400885, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.897407792400885, 'final_confidence': 0.897407792400885}"
med:pmid:41377094,med:pmid:41377094:sec:introduction:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17).",2025-11-04,,introduction,7,1,0.8855572812966265,other,1.0,0.8855572812966265,0.8855572812966265,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8855572812966265, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8855572812966265, 'final_confidence': 0.8855572812966265}"
med:pmid:40839760,med:pmid:40839760:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan.,2025-11-01,,results,5,1,0.878855954288881,randomized controlled trial,1.6,1.4061695268622096,1.4061695268622096,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.878855954288881, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.4061695268622096, 'final_confidence': 1.4061695268622096}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:14,enalapril,ACEI,sacubitril_valsartan,ARNI,"No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups.",2025-11-01,,abstract,14,1,0.8805265167996554,other,1.0,0.8805265167996554,0.8805265167996554,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8805265167996554, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8805265167996554, 'final_confidence': 0.8805265167996554}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05).",2025-11-01,,abstract,15,1,0.8805265167996554,other,1.0,0.8805265167996554,0.8805265167996554,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8805265167996554, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8805265167996554, 'final_confidence': 0.8805265167996554}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate.",2025-11-01,,abstract,5,1,0.8805265167996554,other,1.0,0.8805265167996554,0.8805265167996554,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8805265167996554, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8805265167996554, 'final_confidence': 0.8805265167996554}"
med:pmid:41287294,med:pmid:41287294:sec:abstract:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients.,2025-11-01,,abstract,9,1,0.8805265167996554,other,1.0,0.8805265167996554,0.8805265167996554,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8805265167996554, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8805265167996554, 'final_confidence': 0.8805265167996554}"
med:pmid:41151613,med:pmid:41151613:sec:abstract:sent:2,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"Since 2021, evidence‑based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological ""pillars"": β‑blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid‑receptor antagonists, and sodium-glucose co‑transporter‑2 (SGLT‑2) inhibitors.",2025-10-28,,abstract,2,1,0.8738632593766845,review,0.9,0.786476933439016,0.786476933439016,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8738632593766845, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.786476933439016, 'final_confidence': 0.786476933439016}"
med:pmid:41136931,med:pmid:41136931:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Target dose attainment varied by drug class: 78% for beta-blockers, 63% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",2025-10-24,,results,7,1,0.8672504251932615,other,1.0,0.8672504251932615,0.8672504251932615,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8672504251932615, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8672504251932615, 'final_confidence': 0.8672504251932615}"
med:pmid:41084891,med:pmid:41084891:sec:conclusion:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"However, only 64 patients (22.3%) attained the 4‑pillar GDMT of SGLT2i, ARNI/ACEI/ARB, β‑blockers, and MRA at doses equal to or above 50% of the target dose. In the Polish multicenter HEROES registry, over 80% of the patients with HFrEF were discharged on 4‑pillar GDMT.",2025-10-14,,conclusion,6,1,0.8509364444512367,observational study,1.2,1.021123733341484,1.021123733341484,"['combination', 'registry']","{""combination"": [""arni/acei/arb"", ""gdmt""], ""study_context"": [""registry""], ""real_world_terms"": [""registry""]}","['relationship:combination', 'study_context', 'real_world_terms']",[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8509364444512367, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.021123733341484, 'final_confidence': 1.021123733341484}"
med:pmid:41084891,med:pmid:41084891:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"In this subgroup, the use of angiotensin receptor‑neprilysin inhibitor (ARNI) / angiotensin‑converting enzyme inhibitor (ACEI) / angiotensin receptor blocker (ARB) increased from 81.5% of the patients at admission to 88.9% at discharge, of β‑blocker from 85% to 94.4%, of mineralocorticoid receptor antagonist (MRA) from 69.7% to 86.1%, and of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) from 59.2% to 83.6%.",2025-10-14,,results,4,1,0.8509364444512367,observational study,1.2,1.021123733341484,1.021123733341484,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8509364444512367, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.021123733341484, 'final_confidence': 1.021123733341484}"
med:pmid:41084891,med:pmid:41084891:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI/ACEI/ARB therapy was optimized in 36.2% of the participants, while the rates of optimization were 24.7%, 27.2%, and 24.4% for β‑blockers, MRA, and SGLT2i, respectively.",2025-10-14,,results,5,1,0.8509364444512367,observational study,1.2,1.021123733341484,1.021123733341484,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8509364444512367, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.021123733341484, 'final_confidence': 1.021123733341484}"
med:pmid:41079061,med:pmid:41079061:sec:introduction:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Medications analyzed included ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-10-09,,introduction,4,1,0.842894899250724,observational study,1.2,1.0114738791008688,1.0114738791008688,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.842894899250724, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0114738791008688, 'final_confidence': 1.0114738791008688}"
med:pmid:41079061,med:pmid:41079061:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Other comparisons of price affordability were made against the mean daily salary of managers, professional and non-professional workers in the country. The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.",2025-10-09,,results,6,1,0.842894899250724,observational study,1.2,1.0114738791008688,1.0114738791008688,['combination'],"{""combination"": [""gdmt""], ""access_terms"": [""affordability""]}","['relationship:combination', 'access_terms']",[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.842894899250724, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 1.0114738791008688, 'final_confidence': 1.0114738791008688}"
med:pmid:41016569,med:pmid:41016569:sec:conclusion:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"ARNI therapy also significantly reduced MACEs risk (HR = 0.392, 95 % CI: 0.194-0.791, P = 0.009). Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.",2025-09-26,,conclusion,4,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41016569,med:pmid:41016569:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,To compare the effects of early angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy on left ventricular remodeling and heart failure progression in patients with acute anterior wall myocardial infarction.<h4>Methods</h4>Patients were stratified by treatment into ARNI (n = 97) and ACEI/ARB (n = 71) groups.,2025-09-26,,methods,1,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41016569,med:pmid:41016569:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"Baseline characteristics, cardiac ultrasound data (baseline, 0-3 months, 6-12 months), and major adverse cardiac events (MACEs) were analyzed. The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group.",2025-09-26,,results,2,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41079587,med:pmid:41079587:sec:conclusion:sent:9,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Subgroup analyses demonstrated consistent benefits across all prespecified strata. Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality.",2025-09-26,,conclusion,9,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,"['vs', 'risk']","{""comparative_terms"": [""vs""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41079587,med:pmid:41079587:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy. To evaluate the impact of early sacubitril/valsartan therapy on the 1-year cumulative incidence of AF in patients with AMI complicated by MR.<h4>Methods</h4>In this single-center retrospective cohort, 1,065 in-patients with AMI complicated by MR (June 2021-December 2023) were categorized by discharge prescription into the Sacubitril/Valsartan group (<i>n</i> = 427) or the ACEI/ARB group (<i>n</i> = 638).The primary endpoint was new-onset AF within 1 year.",2025-09-26,,methods,2,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,"['risk', 'cohort', 'retrospective']","{""risk_terms"": [""risk""], ""study_context"": [""cohort"", ""retrospective""], ""endpoint_terms"": [""primary endpoint""], ""real_world_terms"": [""retrospective""]}","['risk_terms', 'study_context', 'endpoint_terms', 'real_world_terms']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41079587,med:pmid:41079587:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,"Prespecified subgroup analyses were performed to assess treatment-effect consistency. Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i> = 0.002).",2025-09-26,,results,6,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,"['vs', 'risk']","{""comparative_terms"": [""vs""], ""risk_terms"": [""risk""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41296625,med:pmid:41296625:sec:conclusion:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNI,"Patients with a number of neurohormonal drugs either unchanged or increased had a lower risk of mortality (odds ratio 0.71, 95% confidence interval 0.53-0.95, P = 0.023). ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival.",2025-09-26,,conclusion,7,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41296625,med:pmid:41296625:sec:conclusion:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.,2025-09-26,,conclusion,8,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41296625,med:pmid:41296625:sec:methods:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNI,"At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.",2025-09-26,,methods,3,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41296625,med:pmid:41296625:sec:methods:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,"Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities.",2025-09-26,,methods,4,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:41296625,med:pmid:41296625:sec:methods:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNI,"Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P = 0.577 and P = 0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P = 0.575).",2025-09-26,,methods,5,1,0.8223407457700268,other,1.0,0.8223407457700268,0.8223407457700268,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.8223407457700268, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8223407457700268, 'final_confidence': 0.8223407457700268}"
med:pmid:40993994,med:pmid:40993994:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the total population, from admission to discharge there was a increase in the use of angiotensin receptor-neprilysin inhibitor (ARNI) (17.1% to 34.3%), beta-blockers (69.4% to 92.4%), mineralocorticoid receptor antagonists (MRA) (44.0% to 82.1%) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) (30.8% to 79.9%), with a reduction in angiotensin-converting enzyme inhibitor (ACEI) use (all p < 0.05).",2025-09-24,,introduction,3,1,0.8192233644907857,other,1.0,0.8192233644907857,0.8192233644907857,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8192233644907857, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8192233644907857, 'final_confidence': 0.8192233644907857}"
med:pmid:40993994,med:pmid:40993994:sec:introduction:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similar trends were observed across HF phenotypes, including HFrEF (increased use of ARNI, 26.3% to 55.1%, beta-blockers, 69.8% to 95.3%, MRA 49.5% to 89.0%, and SGLT2I 36.2% to 79.8%, and lower ACEI use, all p < 0.05).",2025-09-24,,introduction,4,1,0.8192233644907857,other,1.0,0.8192233644907857,0.8192233644907857,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8192233644907857, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8192233644907857, 'final_confidence': 0.8192233644907857}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,"Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven.",2025-09-15,,introduction,1,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"At the 6-week follow-up, in both subgroups, a significant improvement in the median LVEF values was achieved-from a median LVEF value of 30% (27.3; 38) to 37% (30; 43; <i>p</i> = 0.0008) in the ARNI subgroup and from a median LVEF value of 36% (33; 39) to 45% (42; 52; <i>p</i> < 0.0001) in the ACEI/ARB subgroup.",2025-09-15,,introduction,10,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"The median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), <i>p</i> = 0.018].",2025-09-15,,introduction,11,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similarly, the median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), <i>p</i> = 0.047].",2025-09-15,,introduction,12,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,"Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB.",2025-09-15,,introduction,15,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],"{""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function.,2025-09-15,,introduction,2,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,The study population was categorized into pts receiving ARNI and ACEI/ARB.,2025-09-15,,introduction,5,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:introduction:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Finally, two groups (ARNI vs. ACEI/ARB) of 30 pts were obtained and analyzed at baseline and at a 6-week follow-up.",2025-09-15,,introduction,7,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:41007826,med:pmid:41007826:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis.,2025-09-15,,introduction,0,1,0.8053407458618299,other,1.0,0.8053407458618299,0.8053407458618299,"['compared with', 'retrospective']","{""comparative_terms"": [""compared with""], ""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.8053407458618299, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.8053407458618299, 'final_confidence': 0.8053407458618299}"
med:pmid:40916703,med:pmid:40916703:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC).",2025-09-08,,introduction,1,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
med:pmid:40916703,med:pmid:40916703:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid).,2025-09-08,,results,4,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
med:pmid:40916703,med:pmid:40916703:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.,2025-09-08,,results,0,1,0.7931982637077621,other,1.0,0.7931982637077621,0.7931982637077621,"['versus', 'trial']","{""comparative_terms"": [""versus""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.7,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7931982637077621, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7931982637077621, 'final_confidence': 0.7931982637077621}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.,2025-09-08,,conclusion,13,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],"{""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:1,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"/Objectives: Angiotensin receptor-neprilysin inhibitor (AR-NI) has a well-established advantage over angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction the advantage of ARNI has not been clearly proven.",2025-09-08,,introduction,1,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function.,2025-09-08,,introduction,2,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,The study population was catego-rized into pts receiving ARNI and ACEI/ARB.,2025-09-08,,methods,4,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,Finally two groups (ARNI vs ACEI/ARB) of 30 pts were obtained and an-alysed at baseline and in 6-week follow-up.,2025-09-08,,methods,6,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018].",2025-09-08,,results,10,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"Similarly median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047].",2025-09-08,,results,11,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p&amp;lt;0.0001) in ACEI/ARB subgroup.,2025-09-08,,results,9,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,[],"{""claim_strength_terms"": {""confirmatory"": [""p="", ""significant improvement""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
ppr:doi:10.20944/preprints202509.0619.v1,ppr:doi:10.20944/preprints202509.0619.v1:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis,2025-09-08,,results,0,1,0.7947060048529351,other,1.0,0.7947060048529351,0.7947060048529351,"['compared with', 'retrospective']","{""comparative_terms"": [""compared with""], ""study_context"": [""retrospective""], ""real_world_terms"": [""retrospective""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],evidence,real_world,0.72,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7947060048529351, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7947060048529351, 'final_confidence': 0.7947060048529351}"
med:pmid:40910162,med:pmid:40910162:sec:results:sent:6,enalapril,ACE inhibitor,sacubitril_valsartan,ARNi,"A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+β-blockers (BB)+sodium-glucose cotransporter 2 inhibitors (SGLT2i; MD, +5.3 [+0.4, +10.3]) was the most effective at improving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were not statistically significant.",2025-09-05,,results,6,1,0.7901913575916196,review,0.9,0.7111722218324577,0.7111722218324577,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7901913575916196, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.7111722218324577, 'final_confidence': 0.7111722218324577}"
med:pmid:40981086,med:pmid:40981086:sec:abstract:sent:10,enalapril,ACE inhibitors,sacubitril_valsartan,Sacubitril/Valsartan,"While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence.",2025-09-05,,abstract,10,1,0.7901913575916196,other,1.0,0.7901913575916196,0.7901913575916196,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7901913575916196, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7901913575916196, 'final_confidence': 0.7901913575916196}"
med:pmid:40981086,med:pmid:40981086:sec:abstract:sent:12,enalapril,ACE inhibitors,sacubitril_valsartan,sacubitril/valsartan,"This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors.",2025-09-05,,abstract,12,1,0.7901913575916196,other,1.0,0.7901913575916196,0.7901913575916196,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7901913575916196, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7901913575916196, 'final_confidence': 0.7901913575916196}"
med:pmid:40908036,med:pmid:40908036:sec:abstract:sent:5,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-09-04,,abstract,5,1,0.7886921817767578,review,0.9,0.709822963599082,0.709822963599082,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7886921817767578, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.709822963599082, 'final_confidence': 0.709822963599082}"
med:pmid:41049960,med:pmid:41049960:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",2025-09-02,,introduction,1,1,0.7857023576008287,other,1.0,0.7857023576008287,0.7857023576008287,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7857023576008287, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7857023576008287, 'final_confidence': 0.7857023576008287}"
med:pmid:41049960,med:pmid:41049960:sec:methods:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"GDMT use and dosing (none, <50%, ≥50 to <100%, 100% target dose) for beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i were assessed.",2025-09-02,,methods,6,1,0.7857023576008287,other,1.0,0.7857023576008287,0.7857023576008287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7857023576008287, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7857023576008287, 'final_confidence': 0.7857023576008287}"
med:pmid:41049960,med:pmid:41049960:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment.",2025-09-02,,results,11,1,0.7857023576008287,other,1.0,0.7857023576008287,0.7857023576008287,['combination'],"{""combination"": [""acei/arb/arni""], ""endpoint_terms"": [""blood pressure""]}","['relationship:combination', 'endpoint_terms']",[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7857023576008287, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7857023576008287, 'final_confidence': 0.7857023576008287}"
med:pmid:41049960,med:pmid:41049960:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Descriptive statistics and logistic regression models were used to examine patient characteristics and treatment patterns. Among 236 eligible patients, only 16.5%, 10.2%, 31.4%, and 42.8% were receiving target doses of beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i, respectively.",2025-09-02,,results,7,1,0.7857023576008287,other,1.0,0.7857023576008287,0.7857023576008287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7857023576008287, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7857023576008287, 'final_confidence': 0.7857023576008287}"
med:pmid:41070303,med:pmid:41070303:sec:conclusion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.,2025-09-01,,conclusion,10,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],positioning,combination,0.85,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This study compares the efficacy and safety of LBBP combined with sacubitril/valsartan and LBBP combined with enalapril in treating elderly coronary heart disease (CHD) patients with chronic heart failure (CHF).,2025-09-01,,introduction,2,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,"['combination', 'safety']","{""combination"": [""combined with""], ""risk_terms"": [""safety""]}","['relationship:combination', 'risk_terms']",[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups.",2025-09-01,,methods,4,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.",2025-09-01,,results,7,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05).",2025-09-01,,results,8,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41070303,med:pmid:41070303:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.,2025-09-01,,results,0,1,0.7827238674393727,other,1.0,0.7827238674393727,0.7827238674393727,"['combination', 'safety']","{""combination"": [""combined with""], ""risk_terms"": [""safety""]}","['relationship:combination', 'risk_terms']",[],add_on,add_on,add_on,['combination_with'],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7827238674393727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7827238674393727, 'final_confidence': 0.7827238674393727}"
med:pmid:41284794,med:pmid:41284794:sec:abstract:sent:8,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"The last NICE guidelines in 2018 proposed as a second stage one or more of the following interventions delivered by a specialist: angiotensin receptor/neprilysin antagonist (ARNI) instead of ACE inhibitor, ivabradine if in sinus rhythm with a heart rate >70 bpm, a combined hydralazine and nitrate if the patient is of Afro-Caribbean origin, and/or digoxin.",2025-09-01,,abstract,8,1,0.7842116984574725,review,0.9,0.7057905286117253,0.7057905286117253,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7842116984574725, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.7057905286117253, 'final_confidence': 0.7057905286117253}"
med:pmid:40849246,med:pmid:40849246:sec:introduction:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator.",2025-08-22,,introduction,5,1,0.767999928737488,other,1.0,0.767999928737488,0.767999928737488,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.767999928737488, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.767999928737488, 'final_confidence': 0.767999928737488}"
med:pmid:40849246,med:pmid:40849246:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.",2025-08-22,,results,8,1,0.767999928737488,other,1.0,0.767999928737488,0.767999928737488,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,POS,2.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.767999928737488, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.767999928737488, 'final_confidence': 0.767999928737488}"
med:pmid:40869719,med:pmid:40869719:sec:abstract:sent:4,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"The review examines the efficacy of pharmacological therapies and their impact on readmission rates, highlighting key interventions such as diuretics, beta-blockers, ACE inhibitors, ARBs, ARNIs, SGLT2 inhibitors, and intravenous iron supplementation.",2025-08-21,,abstract,4,1,0.767999928737488,review,0.9,0.6911999358637392,0.6911999358637392,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.767999928737488, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6911999358637392, 'final_confidence': 0.6911999358637392}"
med:pmid:40835081,med:pmid:40835081:sec:abstract:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01).",2025-08-18,,abstract,8,1,0.7636369960884427,other,1.0,0.7636369960884427,0.7636369960884427,"['vs', 'combination']","{""comparative_terms"": [""vs""], ""combination"": [""acei/arb/arni""]}","['comparative_terms', 'relationship:combination']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7636369960884427, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7636369960884427, 'final_confidence': 0.7636369960884427}"
med:pmid:40873622,med:pmid:40873622:sec:conclusion:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"During the 1-year follow-up, patients with MEE over 178 kcal/min were associated with increased risk of all-cause death compared with those with MEE below 178 kcal/min. ARNI significantly reduced MEE compared with ACEI/ARB.",2025-08-12,,conclusion,8,1,0.7549853461707969,other,1.0,0.7549853461707969,0.7549853461707969,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""increased risk"", ""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7549853461707969, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7549853461707969, 'final_confidence': 0.7549853461707969}"
med:pmid:40873622,med:pmid:40873622:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%).",2025-08-12,,introduction,3,1,0.7549853461707969,other,1.0,0.7549853461707969,0.7549853461707969,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7549853461707969, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7549853461707969, 'final_confidence': 0.7549853461707969}"
med:pmid:40873622,med:pmid:40873622:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"The main outcome measures were the changes in myocardial energy expenditure (MEE) and prognostic indicators after 1-year follow-up. ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61 ± 40.81) kcal/min vs. (154.49 ± 47.58) kcal/min, <i>P</i> < 0.01].",2025-08-12,,results,4,1,0.7549853461707969,other,1.0,0.7549853461707969,0.7549853461707969,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7549853461707969, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7549853461707969, 'final_confidence': 0.7549853461707969}"
med:pmid:40788620,med:pmid:40788620:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"The CARE-HK in HF registry sought to characterize prospectively the clinical profile, management, and outcomes for patients with HF at high risk of hyperkalaemia. CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).",2025-08-11,,results,2,1,0.7535529643044551,other,1.0,0.7535529643044551,0.7535529643044551,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7535529643044551, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7535529643044551, 'final_confidence': 0.7535529643044551}"
med:pmid:40788620,med:pmid:40788620:sec:results:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin-angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events.",2025-08-11,,results,4,1,0.7535529643044551,other,1.0,0.7535529643044551,0.7535529643044551,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7535529643044551, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7535529643044551, 'final_confidence': 0.7535529643044551}"
med:pmid:40769236,med:pmid:40769236:sec:conclusion:sent:6,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Statin use was notably low among patients with chronic kidney disease (CKD) (18.1%), diabetes mellitus type 2 (15.8%), and both conditions combined (3.2%). Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia.",2025-08-05,,conclusion,6,1,0.7450155617493656,other,1.0,0.7450155617493656,0.7450155617493656,[],,[],['chronic kidney disease'],,,,[],,,,,,,,"{'recency_weight': 0.7450155617493656, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7450155617493656, 'final_confidence': 0.7450155617493656}"
med:pmid:40769236,med:pmid:40769236:sec:introduction:sent:2,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"Effective metabolic control and risk factor management, including evidence-based pharmacological therapies such as statins, ACE inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential for reducing adverse outcomes.",2025-08-05,,introduction,2,1,0.7450155617493656,other,1.0,0.7450155617493656,0.7450155617493656,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7450155617493656, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7450155617493656, 'final_confidence': 0.7450155617493656}"
med:pmid:40397431,med:pmid:40397431:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.,2025-08-01,,introduction,2,1,0.7393777639348282,other,1.0,0.7393777639348282,0.7393777639348282,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.7393777639348282, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7393777639348282, 'final_confidence': 0.7393777639348282}"
med:pmid:40397431,med:pmid:40397431:sec:introduction:sent:6,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male].",2025-08-01,,introduction,6,1,0.7393777639348282,other,1.0,0.7393777639348282,0.7393777639348282,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7393777639348282, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7393777639348282, 'final_confidence': 0.7393777639348282}"
med:pmid:40397431,med:pmid:40397431:sec:introduction:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively.",2025-08-01,,introduction,7,1,0.7393777639348282,other,1.0,0.7393777639348282,0.7393777639348282,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.7393777639348282, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7393777639348282, 'final_confidence': 0.7393777639348282}"
med:pmid:40397431,med:pmid:40397431:sec:introduction:sent:8,enalapril,ACEI,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).,2025-08-01,,introduction,8,1,0.7393777639348282,other,1.0,0.7393777639348282,0.7393777639348282,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.7393777639348282, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7393777639348282, 'final_confidence': 0.7393777639348282}"
ppr:doi:10.21203/rs.3.rs-7118793/v1,ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Target dose attainment varied by drug class: 46% for beta-blockers, 41% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",2025-08-01,,results,10,1,0.7393777639348282,other,1.0,0.7393777639348282,0.7393777639348282,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7393777639348282, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7393777639348282, 'final_confidence': 0.7393777639348282}"
med:pmid:41126807,med:pmid:41126807:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"For non-pharmacologic management, referral to HF specialty was made in 30% and cardiac rehabilitation in 22.2%. Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.",2025-07-31,,conclusion,12,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the 3<sup>rd</sup> month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively.",2025-07-31,,results,11,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.",2025-07-31,,results,7,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:41126807,med:pmid:41126807:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,"Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).",2025-07-31,,results,9,1,0.7379749932627773,other,1.0,0.7379749932627773,0.7379749932627773,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.7379749932627773, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7379749932627773, 'final_confidence': 0.7379749932627773}"
med:pmid:40791946,med:pmid:40791946:sec:results:sent:12,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"RAAS inhibitors including ACE inhibitors (18.1%), ARBs (25.2%), and ARNI (10.8%), were also frequently used.",2025-07-28,,results,12,1,0.7337826293421476,other,1.0,0.7337826293421476,0.7337826293421476,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7337826293421476, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7337826293421476, 'final_confidence': 0.7337826293421476}"
med:pmid:40727001,med:pmid:40727001:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"LASSO regression showed that the key predictors included age, BNP, New York Heart Association (NYHA) class, LVEF, PLR, MLR, AF history, and ACEI/ARB/ARNI usage.",2025-07-24,,results,7,1,0.7282298351235453,other,1.0,0.7282298351235453,0.7282298351235453,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7282298351235453, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7282298351235453, 'final_confidence': 0.7282298351235453}"
med:pmid:40689605,med:pmid:40689605:sec:conclusion:sent:6,enalapril,ACEIs,sacubitril_valsartan,ARNI,"However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04-1.71; <i>p</i> = 0.024). initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.<h4>Protocol registration</h4>PROSPERO: CRD42024618027.",2025-07-21,,conclusion,6,1,0.7240928324953128,review,0.9,0.6516835492457815,0.6516835492457815,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""albeit with"", ""higher symptomatic""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],alternative,disfavored,favored,['preferred_over'],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7240928324953128, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6516835492457815, 'final_confidence': 0.6516835492457815}"
med:pmid:40689605,med:pmid:40689605:sec:methods:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNI,"This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF. Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024.",2025-07-21,,methods,3,1,0.7240928324953128,review,0.9,0.6516835492457815,0.6516835492457815,"['versus', 'meta-analysis', 'randomized']","{""comparative_terms"": [""versus""], ""study_context"": [""meta-analysis"", ""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7240928324953128, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6516835492457815, 'final_confidence': 0.6516835492457815}"
med:pmid:40679772,med:pmid:40679772:sec:conclusion:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among all patients in our study, 61.6% received either an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI); 57.0% were prescribed β-blockers; and 32.6% used a sodium-glucose cotransporter 2 inhibitor. While the Beers Criteria identified a greater number of PIMs in this study, both tools have differing strengths in detecting medication-related risks.",2025-07-18,,conclusion,8,1,0.7199793317752973,other,1.0,0.7199793317752973,0.7199793317752973,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.7199793317752973, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7199793317752973, 'final_confidence': 0.7199793317752973}"
med:pmid:40660106,med:pmid:40660106:sec:discussion:sent:6,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs. Foundational therapies were widely prescribed and frequently initiated concurrently in the management of HFrEF at a tertiary care hospital in Vietnam.",2025-07-14,,discussion,6,1,0.7145309920202676,other,1.0,0.7145309920202676,0.7145309920202676,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7145309920202676, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7145309920202676, 'final_confidence': 0.7145309920202676}"
med:pmid:40755965,med:pmid:40755965:sec:title:sent:0,enalapril,ACEi,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis.,2025-07-11,,title,0,1,0.7104718111828882,other,1.0,0.7104718111828882,0.7104718111828882,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.7104718111828882, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.7104718111828882, 'final_confidence': 0.7104718111828882}"
ppr:doi:10.21203/rs.3.rs-6768681/v1,ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"While therapy with beta blockers and ACEI/ARB/ARNI was common within the cohort, only a third of the cohort was treated with SGLT2 inhibitors or mineralocorticoid receptor antagonists.",2025-06-25,,results,10,1,0.6892091206123461,other,1.0,0.6892091206123461,0.6892091206123461,"['combination', 'cohort']","{""combination"": [""acei/arb/arni""], ""study_context"": [""cohort""]}","['relationship:combination', 'study_context']",[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.6892091206123461, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6892091206123461, 'final_confidence': 0.6892091206123461}"
med:pmid:40542996,med:pmid:40542996:sec:results:sent:11,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNi,"The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi + SGLT2i (2.2%).",2025-06-21,,results,11,1,0.6839936299924942,review,0.9,0.6155942669932448,0.6155942669932448,['combination'],"{""combination"": [""acei/arb/arni"", ""triple therapy""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6839936299924942, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.6155942669932448, 'final_confidence': 0.6155942669932448}"
med:pmid:40540017,med:pmid:40540017:sec:abstract:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNI,CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA).,2025-06-20,,abstract,4,1,0.6826959358355629,other,1.0,0.6826959358355629,0.6826959358355629,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6826959358355629, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6826959358355629, 'final_confidence': 0.6826959358355629}"
med:pmid:40540017,med:pmid:40540017:sec:abstract:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNI,"Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA.",2025-06-20,,abstract,8,1,0.6826959358355629,other,1.0,0.6826959358355629,0.6826959358355629,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6826959358355629, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6826959358355629, 'final_confidence': 0.6826959358355629}"
med:pmid:40543460,med:pmid:40543460:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"Quality metrics included antiplatelet and statin or proprotein convertase subtilisin/kexin type 9 inhibitor therapy for atherosclerotic cardiovascular disease prevention, blood pressure control, and GDMT for heart failure with reduced ejection fraction (HFrEF; specified beta blockers; ACEI, ARB, or ARNI; mineralocorticoid receptor antagonist).",2025-06-20,,introduction,3,1,0.6826959358355629,other,1.0,0.6826959358355629,0.6826959358355629,[],,[],['cardiovascular disease'],,,,[],,,,,,,,"{'recency_weight': 0.6826959358355629, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6826959358355629, 'final_confidence': 0.6826959358355629}"
med:pmid:40575771,med:pmid:40575771:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Currently, GDMT recommendations mainly include five types of drugs: diuretics, angiotensin receptor-neprilysin inhibitors (ARNIs), renin-angiotensin system inhibitors (ACEIs/ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i).",2025-06-12,,results,9,1,0.6724026242651086,other,1.0,0.6724026242651086,0.6724026242651086,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6724026242651086, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6724026242651086, 'final_confidence': 0.6724026242651086}"
med:pmid:40470816,med:pmid:40470816:sec:conclusion:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNi,"A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis. In this large nationwide real-world population with HFrEF, CRT implantation was associated with enabled use/dose of heart failure GDMT and decreased loop diuretic need (use/dose).",2025-06-05,,conclusion,7,1,0.6635233668830569,other,1.0,0.6635233668830569,0.6635233668830569,"['combination', 'real-world']","{""combination"": [""acei/arb/arni"", ""gdmt""], ""study_context"": [""real-world""], ""real_world_terms"": [""real-world""]}","['relationship:combination', 'study_context', 'real_world_terms']",[],,,,[],positioning,combination,0.6499999999999999,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6635233668830569, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6635233668830569, 'final_confidence': 0.6635233668830569}"
med:pmid:40470816,med:pmid:40470816:sec:introduction:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNi,"At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonist (MRA) and loop diuretic use was 84% versus 86%, 89% versus 88%, 57% versus 46% and 62% versus 59% in patients receiving versus not receiving CRT, respectively.",2025-06-05,,introduction,4,1,0.6635233668830569,other,1.0,0.6635233668830569,0.6635233668830569,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6635233668830569, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6635233668830569, 'final_confidence': 0.6635233668830569}"
med:pmid:40448468,med:pmid:40448468:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNi,"While HF guidelines recommend initiation of quadruple guideline-directed medical therapy (GDMT) in patients with HF with reduced ejection fraction (HFrEF), in-hospital initiation of quadruple therapy remains a clinical challenge, particularly in patients with additional high-risk comorbidities. The purpose of this study was to compare the efficacy and safety of triple GDMT with a sodium-glucose cotransporter inhibitor (SGLTi) vs mineralocorticoid receptor antagonist (MRA) added to beta blocker and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNi).<h4>Methods</h4>This retrospective cohort study was conducted in hospitalized patients with acute HFrEF.",2025-05-31,,methods,2,1,0.6572529183893066,other,1.0,0.6572529183893066,0.6572529183893066,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6572529183893066, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6572529183893066, 'final_confidence': 0.6572529183893066}"
med:pmid:40448468,med:pmid:40448468:sec:introduction:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNi,Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared.,2025-05-31,,introduction,3,1,0.6572529183893066,other,1.0,0.6572529183893066,0.6572529183893066,"['add-on therapy', 'combination']","{""combination"": [""acei/arb/arni"", ""gdmt""], ""add-on therapy"": [""added to""]}","['relationship:add-on therapy', 'relationship:combination']",[],add_on,backbone,add_on,['add_on_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6572529183893066, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6572529183893066, 'final_confidence': 0.6572529183893066}"
med:pmid:40450497,med:pmid:40450497:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).<h4>Method</h4>Five (5) databases were searched for randomised controlled trials (RCTs) comparing S/V vs ACEI or ARB in adult patients with HF until 2 September 2023.,2025-05-30,,introduction,1,1,0.6560059575487075,review,0.9,0.5904053617938367,0.5904053617938367,"['vs', 'randomised']","{""comparative_terms"": [""vs""], ""study_context"": [""randomised""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6560059575487075, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.5904053617938367, 'final_confidence': 0.5904053617938367}"
med:pmid:40418165,med:pmid:40418165:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs.",2025-05-26,,introduction,2,1,0.6510417270766522,review,0.9,0.585937554368987,0.585937554368987,[],,[],[],,,,[],,,,NEU,0.5,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6510417270766522, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.585937554368987, 'final_confidence': 0.585937554368987}"
med:pmid:40418165,med:pmid:40418165:sec:methods:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNIs,This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI. Randomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases.,2025-05-26,,methods,3,1,0.6510417270766522,review,0.9,0.585937554368987,0.585937554368987,"['versus', 'safety', 'meta-analysis', 'randomized']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""meta-analysis"", ""randomized""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.6510417270766522, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.585937554368987, 'final_confidence': 0.585937554368987}"
med:pmid:40389107,med:pmid:40389107:sec:introduction:sent:1,enalapril,ACEIs,sacubitril_valsartan,sacubitril/valsartan,This study investigated the effect of uptitration of sacubitril/valsartan (Sac/Val) compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level within current guideline-directed medical therapy in acute heart failure (AHF).<h4>Methods and results</h4>This was the secondary analysis in the Program Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study.,2025-05-17,,results,1,1,0.6400091266891378,other,1.0,0.6400091266891378,0.6400091266891378,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEG,-3.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6400091266891378, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6400091266891378, 'final_confidence': 0.6400091266891378}"
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.",2025-05-12,,discussion,10,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,['versus'],"{""comparative_terms"": [""versus""], ""claim_strength_terms"": {""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:discussion:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs.",2025-05-12,,discussion,8,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52 weeks.,2025-05-12,,introduction,1,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This post hoc analysis aims to correlate changes in NT-proBNP levels with clinical outcomes in PANORAMA-HF patients receiving either sacubitril/valsartan or enalapril.,2025-05-12,,introduction,2,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40353367,med:pmid:40353367:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed.",2025-05-12,,results,5,1,0.6327581226956497,randomized controlled trial,1.6,1.0124129963130395,1.0124129963130395,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.9,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6327581226956497, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 1.0124129963130395, 'final_confidence': 1.0124129963130395}"
med:pmid:40319618,med:pmid:40319618:sec:conclusion:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Scenario analysis demonstrated that initiation of ARNI alongside sodium-glucose cotransporter-2 inhibitor (SGLT-2i) produces more favorable ICER and ARNI without SGLT-2i. At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population.",2025-05-03,,conclusion,10,1,0.6232177458400726,other,1.0,0.6232177458400726,0.6232177458400726,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6232177458400726, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6232177458400726, 'final_confidence': 0.6232177458400726}"
med:pmid:40319618,med:pmid:40319618:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"This study compared the costs and effectiveness of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) for the heart failure with reduced ejection fraction population from the Malaysian Ministry of Health's perspective.<h4>Methods</h4>A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI.",2025-05-03,,methods,1,1,0.6232177458400726,other,1.0,0.6232177458400726,0.6232177458400726,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6232177458400726, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6232177458400726, 'final_confidence': 0.6232177458400726}"
med:pmid:40319618,med:pmid:40319618:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"The ICER was compared with Malaysian Ringgit (RM) 55 426 per QALY (one gross domestic product per capita). Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY.",2025-05-03,,results,6,1,0.6232177458400726,other,1.0,0.6232177458400726,0.6232177458400726,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6232177458400726, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6232177458400726, 'final_confidence': 0.6232177458400726}"
med:pmid:40332281,med:pmid:40332281:sec:conclusion:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNi,"We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers.",2025-05-02,,conclusion,12,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,POS,1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,ARNi,"Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers.",2025-05-02,,results,10,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,ARNi,"93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate.",2025-05-02,,results,8,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40332281,med:pmid:40332281:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,ARNi,"71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone.",2025-05-02,,results,9,1,0.620855212615535,observational study,1.2,0.745026255138642,0.745026255138642,['combination'],"{""combination"": [""gdmt""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.620855212615535, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.745026255138642, 'final_confidence': 0.745026255138642}"
med:pmid:40302030,med:pmid:40302030:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI]; beta-blocker (BB); mineralocorticoid receptor antagonist [MRA]; sodium-glucose co-transporter 2 inhibitor [SGLT2i]) in patients with heart failure and reduced ejection fraction (HFrEF).,2025-04-29,,introduction,1,1,0.6185016354312808,other,1.0,0.6185016354312808,0.6185016354312808,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6185016354312808, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6185016354312808, 'final_confidence': 0.6185016354312808}"
med:pmid:40302030,med:pmid:40302030:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%.",2025-04-29,,results,5,1,0.6185016354312808,other,1.0,0.6185016354312808,0.6185016354312808,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6185016354312808, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6185016354312808, 'final_confidence': 0.6185016354312808}"
med:pmid:40295134,med:pmid:40295134:sec:introduction:sent:3,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"In the ARNI group, if a patient was on an ACE inhibitor or angiotensin II receptor blocker before TAVI, it will be switched to ARNI 100 mg/day (50 mg two times per day) on the first postoperative day.",2025-04-28,,introduction,3,1,0.6173281947395006,other,1.0,0.6173281947395006,0.6173281947395006,['switching'],"{""switching"": [""switched to""]}",['relationship:switching'],[],switch,switch_source,switch_destination,['switch_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6173281947395006, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6173281947395006, 'final_confidence': 0.6173281947395006}"
med:pmid:40268473,med:pmid:40268473:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,The effects of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) on myocardial tissue in heart failure (HF) with left ventricular ejection fraction (LVEF) <50% remain unclear.<h4>Methods and results</h4>Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB).,2025-04-24,,results,1,1,0.6126566526592487,randomized controlled trial,1.6,0.980250644254798,0.980250644254798,"['switching', 'randomized']","{""switching"": [""switching from""], ""study_context"": [""randomized""]}","['relationship:switching', 'study_context']",[],switch,switch_destination,switch_source,['switch_from'],positioning,switching,0.49999999999999994,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6126566526592487, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.980250644254798, 'final_confidence': 0.980250644254798}"
med:pmid:40265590,med:pmid:40265590:sec:conclusion:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In PARADIGM-HF, sacubitril/valsartan, compared with enalapril, reduced the risk of HF hospitalizations, death from cardiovascular causes, and death from any cause similarly in women and men with HF with reduced ejection fraction.",2025-04-23,,conclusion,12,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported.,2025-04-23,,introduction,2,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,['safety'],"{""risk_terms"": [""safety""]}",['risk_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril.,2025-04-23,,results,3,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,['randomized'],"{""study_context"": [""randomized""], ""claim_strength_terms"": {""suggestive"": [""post hoc""]}}","['study_context', 'claim_strength:suggestive']",[],,,,[],evidence,clinical_trial,0.7,POS,1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40265590,med:pmid:40265590:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).",2025-04-23,,results,8,1,0.610334155094308,randomized controlled trial,1.6,0.9765346481508929,0.9765346481508929,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.610334155094308, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.9765346481508929, 'final_confidence': 0.9765346481508929}"
med:pmid:40266448,med:pmid:40266448:sec:conclusion:sent:12,enalapril,ACEi,sacubitril_valsartan,ARNi,"However, no significant benefit was observed in patients with GFR <30 mL/min/1.73 m<sup>2</sup>. In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers.",2025-04-23,,conclusion,12,1,0.6114943012520145,other,1.0,0.6114943012520145,0.6114943012520145,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6114943012520145, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6114943012520145, 'final_confidence': 0.6114943012520145}"
med:pmid:40266448,med:pmid:40266448:sec:methods:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNi,"This study investigated the outcomes of ARNi compared to angiotensin-converting enzyme inhibitors (ACEi) in HF patients with AKD. The study included 20,009 hospitalized HF and AKD patients who underwent dialysis during hospitalization, recovered from dialysis within 90 days after discharge, and were followed until November 30, 2022, using data from TriNetX. The study period began in July 2015, coinciding with the availability of ARNi in the market.",2025-04-23,,methods,3,1,0.6114943012520145,other,1.0,0.6114943012520145,0.6114943012520145,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6114943012520145, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6114943012520145, 'final_confidence': 0.6114943012520145}"
med:pmid:40266448,med:pmid:40266448:sec:methods:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNi,Propensity score matching (1:1) was applied to balance ARNi and ACEi groups.,2025-04-23,,methods,4,1,0.6114943012520145,other,1.0,0.6114943012520145,0.6114943012520145,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.6114943012520145, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6114943012520145, 'final_confidence': 0.6114943012520145}"
med:pmid:40385266,med:pmid:40385266:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,ARNis,"The combination therapy of angiotensin-converting enzyme inhibitors (ACEi) or alternatively angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and recently sodium-glucose co-transporter 2 inhibitors (SGLT2is) has been hailed as a breakthrough in heart failure treatment for patients with structurally normal hearts, with international guidelines recommending these as first-line therapies (""fantastic four"").",2025-04-23,,introduction,1,1,0.6114943012520145,other,1.0,0.6114943012520145,0.6114943012520145,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6114943012520145, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6114943012520145, 'final_confidence': 0.6114943012520145}"
med:pmid:41080832,med:pmid:41080832:sec:abstract:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed.",2025-04-23,,abstract,6,1,0.6114943012520145,other,1.0,0.6114943012520145,0.6114943012520145,[],"{""claim_strength_terms"": {""suggestive"": [""secondary endpoints""]}}",['claim_strength:suggestive'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.6114943012520145, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6114943012520145, 'final_confidence': 0.6114943012520145}"
med:pmid:40261428,med:pmid:40261428:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively.",2025-04-22,,results,6,1,0.610334155094308,other,1.0,0.610334155094308,0.610334155094308,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.610334155094308, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.610334155094308, 'final_confidence': 0.610334155094308}"
med:pmid:40232857,med:pmid:40232857:sec:results:sent:3,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission.",2025-04-15,,results,3,1,0.6022745285304433,observational study,1.2,0.7227294342365319,0.7227294342365319,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6022745285304433, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.7227294342365319, 'final_confidence': 0.7227294342365319}"
med:pmid:40255655,med:pmid:40255655:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age.",2025-04-14,,results,10,1,0.6011318744145693,other,1.0,0.6011318744145693,0.6011318744145693,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6011318744145693, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6011318744145693, 'final_confidence': 0.6011318744145693}"
med:pmid:40255655,med:pmid:40255655:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk.",2025-04-14,,results,11,1,0.6011318744145693,other,1.0,0.6011318744145693,0.6011318744145693,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.6011318744145693, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.6011318744145693, 'final_confidence': 0.6011318744145693}"
med:pmid:40283370,med:pmid:40283370:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)).,2025-04-08,,introduction,2,1,0.5943213315016239,other,1.0,0.5943213315016239,0.5943213315016239,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5943213315016239, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5943213315016239, 'final_confidence': 0.5943213315016239}"
med:pmid:40188960,med:pmid:40188960:sec:conclusion:sent:5,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP. The DbCM-2B diagnostic criteria demonstrated a strong correlation with CMD.",2025-04-04,,conclusion,5,1,0.5898238905407867,other,1.0,0.5898238905407867,0.5898238905407867,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5898238905407867, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5898238905407867, 'final_confidence': 0.5898238905407867}"
med:pmid:40188960,med:pmid:40188960:sec:conclusion:sent:6,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.",2025-04-04,,conclusion,6,1,0.5898238905407867,other,1.0,0.5898238905407867,0.5898238905407867,[],"{""claim_strength_terms"": {""exploratory"": [""might improve""]}}",['claim_strength:exploratory'],[],,,,[],,,,NEU,0.5,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5898238905407867, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5898238905407867, 'final_confidence': 0.5898238905407867}"
med:pmid:40718065,med:pmid:40718065:sec:conclusion:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). A high rate of ACEI/ARB/ARNI and BB use was observed.,2025-04-01,,conclusion,9,1,0.5864731585772334,other,1.0,0.5864731585772334,0.5864731585772334,"['compared to', 'combination']","{""comparative_terms"": [""compared to""], ""combination"": [""acei/arb/arni"", ""triple therapy""], ""claim_strength_terms"": {""confirmatory"": [""p=""]}}","['comparative_terms', 'relationship:combination', 'claim_strength:confirmatory']",[],,,,[],positioning,combination,0.85,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.5864731585772334, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5864731585772334, 'final_confidence': 0.5864731585772334}"
med:pmid:40718065,med:pmid:40718065:sec:results:sent:5,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs).",2025-04-01,,results,5,1,0.5864731585772334,other,1.0,0.5864731585772334,0.5864731585772334,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5864731585772334, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5864731585772334, 'final_confidence': 0.5864731585772334}"
med:pmid:40718065,med:pmid:40718065:sec:results:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014).",2025-04-01,,results,6,1,0.5864731585772334,other,1.0,0.5864731585772334,0.5864731585772334,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5864731585772334, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5864731585772334, 'final_confidence': 0.5864731585772334}"
med:pmid:40105368,med:pmid:40105368:sec:results:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNI,"OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses. Achieving OMT was associated with male sex (OR: 2.05 95%CI 1.44-2.97; <i>p</i> < 0.0001) independently of younger age, higher diastolic blood pressure (DBP), and lower creatinine.",2025-03-31,,results,3,1,0.5853604833157824,other,1.0,0.5853604833157824,0.5853604833157824,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5853604833157824, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5853604833157824, 'final_confidence': 0.5853604833157824}"
med:pmid:40101251,med:pmid:40101251:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"Of these, 95% reached titration to either guideline-recommended target doses or maximum tolerated doses for both angiotensin-converting enzyme inhibitor/angiotensin receptor blockers/angiotensin and angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and beta-blockers combined.",2025-03-18,,results,10,1,0.5710863558696406,observational study,1.2,0.6853036270435687,0.6853036270435687,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5710863558696406, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6853036270435687, 'final_confidence': 0.6853036270435687}"
med:pmid:40101251,med:pmid:40101251:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.",2025-03-18,,results,11,1,0.5710863558696406,observational study,1.2,0.6853036270435687,0.6853036270435687,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5710863558696406, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6853036270435687, 'final_confidence': 0.6853036270435687}"
med:pmid:40091512,med:pmid:40091512:sec:results:sent:3,enalapril,ACEi,sacubitril_valsartan,ARNI,"The GDMT score (0-8) factored in doses of beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor-neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD).",2025-03-17,,results,3,1,0.5700028729326381,other,1.0,0.5700028729326381,0.5700028729326381,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5700028729326381, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5700028729326381, 'final_confidence': 0.5700028729326381}"
med:pmid:40091512,med:pmid:40091512:sec:results:sent:6,enalapril,ACEi,sacubitril_valsartan,ARNI,"Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD.",2025-03-17,,results,6,1,0.5700028729326381,other,1.0,0.5700028729326381,0.5700028729326381,['combination'],"{""combination"": [""acei/arb/arni""]}",['relationship:combination'],[],,,,[],positioning,combination,0.85,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5700028729326381, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5700028729326381, 'final_confidence': 0.5700028729326381}"
ppr:doi:10.1101/2025.03.12.25323680,ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7,enalapril,ACEi,sacubitril_valsartan,ARNi,"The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].",2025-03-14,,results,7,1,0.566764742235861,other,1.0,0.566764742235861,0.566764742235861,[],"{""claim_strength_terms"": {""confirmatory"": [""statistically significant""]}}",['claim_strength:confirmatory'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.760319+00:00,"{'recency_weight': 0.566764742235861, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.566764742235861, 'final_confidence': 0.566764742235861}"
med:pmid:40063170,med:pmid:40063170:sec:conclusion:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNIs,"Notably, 94.8% of prescribed SGLT2I doses met the target dose, while 84.4% of β-blocker prescriptions and 61.8% of ACEI/ARB prescriptions were below 75% of the target dose. The findings reveal significant gaps in the prescription of essential therapies, including MRAs and ARNIs, which are crucial for managing myocardial dysfunction.",2025-03-10,,conclusion,15,1,0.5624758317899755,other,1.0,0.5624758317899755,0.5624758317899755,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5624758317899755, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5624758317899755, 'final_confidence': 0.5624758317899755}"
med:pmid:40063170,med:pmid:40063170:sec:results:sent:14,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"The prescription rates for key medications were as follows: β-blockers 76.4%, ACE inhibitors/ARBs 71.6%, MRA 63.3%, SGLT2I 33.5%, and ARNI 0%.",2025-03-10,,results,14,1,0.5624758317899755,other,1.0,0.5624758317899755,0.5624758317899755,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5624758317899755, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5624758317899755, 'final_confidence': 0.5624758317899755}"
med:pmid:40063170,med:pmid:40063170:sec:results:sent:7,enalapril,ACE inhibitors,sacubitril_valsartan,ARNI,"Medications were classified according to the four-pillar therapy recommended by the AHA, including β-blockers, ARNI, ACE inhibitors/ARBs, SGLT2, and MRAs.",2025-03-10,,results,7,1,0.5624758317899755,other,1.0,0.5624758317899755,0.5624758317899755,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5624758317899755, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5624758317899755, 'final_confidence': 0.5624758317899755}"
med:pmid:39661383,med:pmid:39661383:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,"Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased.",2025-03-01,,results,12,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:introduction:sent:4,enalapril,angiotensin converting enzyme inhibitor,sacubitril_valsartan,ARNI,"Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods.",2025-03-01,,introduction,4,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:introduction:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).",2025-03-01,,introduction,7,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,"['vs', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,"ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711).",2025-03-01,,results,10,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:39661383,med:pmid:39661383:sec:results:sent:11,enalapril,ACEI,sacubitril_valsartan,ARNI,"In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.",2025-03-01,,results,11,1,0.5518950126619467,other,1.0,0.5518950126619467,0.5518950126619467,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.5518950126619467, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5518950126619467, 'final_confidence': 0.5518950126619467}"
med:pmid:40115097,med:pmid:40115097:sec:results:sent:5,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"Statistical comparison between two groups was performed, which focused on indicators of standardized management [proportion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography performed in the diagnosis of HF, application ratio of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), β-blockers in heart failure with reduced ejection fraction (HFrEF) patients, 1 week, 1 month, 3 months and 1 year follow-up rate] and clinical prognosis indicators (NT-proBNP level, 6-minute walking distance test, heart function grading, shorter average duration in hospital) at discharge, review of relevant indicators after 1 year, readmission rate and incidence of main adverse cardiovascular and cerebrovascular events (MACCEs) in 1 year. Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and β-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group.",2025-02-21,,results,5,1,0.5446070906811961,other,1.0,0.5446070906811961,0.5446070906811961,"['compared to', 'vs', 'combination', 'review']","{""comparative_terms"": [""compared to"", ""vs""], ""combination"": [""acei/arb/arni""], ""study_context"": [""review""], ""claim_strength_terms"": {""confirmatory"": [""p=""]}}","['comparative_terms', 'relationship:combination', 'study_context', 'claim_strength:confirmatory']",[],,,,[],positioning,combination,0.6499999999999999,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5446070906811961, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5446070906811961, 'final_confidence': 0.5446070906811961}"
med:pmid:39983618,med:pmid:39983618:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6 months in patients with hematologic malignancies treated with BMT.,2025-02-20,,conclusion,11,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT.,2025-02-20,,introduction,2,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).",2025-02-20,,methods,3,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Patients treated with sacubitril/valsartan or enalapril for 6 months did not show a deterioration of LV GLS or LVEF (P > 0.05).,2025-02-20,,results,6,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P = 0.044 and P = 0.011, respectively) at 6 months.",2025-02-20,,results,8,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39983618,med:pmid:39983618:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.,2025-02-20,,results,0,1,0.542542559697216,other,1.0,0.542542559697216,0.542542559697216,"['randomized', 'randomized controlled trial', 'trial']","{""study_context"": [""randomized"", ""randomized controlled trial"", ""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.542542559697216, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.542542559697216, 'final_confidence': 0.542542559697216}"
med:pmid:39970741,med:pmid:39970741:sec:title:sent:0,enalapril,ACE Inhibitors,sacubitril_valsartan,Sacubitril/Valsartan,Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.,2025-02-18,,title,0,1,0.5415132309451143,other,1.0,0.5415132309451143,0.5415132309451143,"['vs', 'meta-analysis', 'randomized', 'review', 'systematic review']","{""comparative_terms"": [""vs""], ""study_context"": [""meta-analysis"", ""randomized"", ""review"", ""systematic review""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5415132309451143, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5415132309451143, 'final_confidence': 0.5415132309451143}"
med:pmid:40486108,med:pmid:40486108:sec:introduction:sent:2,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as a promising alternative to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HF management.,2025-02-18,,introduction,2,1,0.5415132309451143,other,1.0,0.5415132309451143,0.5415132309451143,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5415132309451143, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5415132309451143, 'final_confidence': 0.5415132309451143}"
med:pmid:40486108,med:pmid:40486108:sec:methods:sent:4,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"This systematic review and meta-analysis aim to evaluate the impact of ARNIs on functional and safety outcomes in this unique patient population. We conducted a systematic review and meta-analysis of published studies assessing the use of ARNIs in ACHD patients with HF, comparing them to ACEIs/ARBs.",2025-02-18,,methods,4,1,0.5415132309451143,other,1.0,0.5415132309451143,0.5415132309451143,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5415132309451143, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5415132309451143, 'final_confidence': 0.5415132309451143}"
med:pmid:40486108,med:pmid:40486108:sec:results:sent:7,enalapril,ACEIs,sacubitril_valsartan,ARNIs,"Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).",2025-02-18,,results,7,1,0.5415132309451143,other,1.0,0.5415132309451143,0.5415132309451143,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.5415132309451143, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5415132309451143, 'final_confidence': 0.5415132309451143}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:10,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Better renal function was a predictor for ACEIs/ARBs/ARNIs at any dose and ≥50% target dose.,2025-02-11,,results,10,1,0.5343624031823536,other,1.0,0.5343624031823536,0.5343624031823536,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5343624031823536, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5343624031823536, 'final_confidence': 0.5343624031823536}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:7,enalapril,ACEIs,sacubitril_valsartan,angiotensin receptor neprilysin inhibitors,"The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers.",2025-02-11,,results,7,1,0.5343624031823536,other,1.0,0.5343624031823536,0.5343624031823536,['vs'],"{""comparative_terms"": [""vs""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5343624031823536, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5343624031823536, 'final_confidence': 0.5343624031823536}"
med:pmid:39939202,med:pmid:39939202:sec:results:sent:9,enalapril,ACEIs,sacubitril_valsartan,ARNIs,Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and ≥50% target dose.,2025-02-11,,results,9,1,0.5343624031823536,other,1.0,0.5343624031823536,0.5343624031823536,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5343624031823536, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5343624031823536, 'final_confidence': 0.5343624031823536}"
med:pmid:39922597,med:pmid:39922597:sec:conclusion:sent:5,enalapril,ACEi,sacubitril_valsartan,ARNi,"Conversely, the prescription of furosemide at discharge (adjusted OR 2.25; 95% CI 95% 1.29 to 3.94; p<0.01) and a previous genitourinary infection (adjusted OR 4.02; 95% CI 1.67 to 9.68; p<0.01) were associated with higher risk of 30-day all-cause death and urgent rehospitalisation. In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi.",2025-02-08,,conclusion,5,1,0.5313267425162138,observational study,1.2,0.6375920910194566,0.6375920910194566,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""higher risk"", ""risk of""]}, ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment', 'claim_strength:confirmatory']",[],,,,[],positioning,combination,0.6499999999999999,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5313267425162138, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6375920910194566, 'final_confidence': 0.6375920910194566}"
med:pmid:39922597,med:pmid:39922597:sec:introduction:sent:2,enalapril,ACE inhibitor,sacubitril_valsartan,ARNi,"The entire cohort was divided into three time periods based on two time points: September 2021 (ie, the release of the latest European guidelines) and January 2022 (ie, reimbursement for sodium-glucose cotransporter 2 (SGLT2) inhibitors).<h4>Primary and secondary outcome measures</h4>Trends and predictors of the prescription of each of the four foundational therapies and of the composite of all-cause death and rehospitalisation for urgent causes at 30 days.<h4>Results</h4>Among the 999 included patients, β-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%.",2025-02-08,,introduction,2,1,0.5313267425162138,observational study,1.2,0.6375920910194566,0.6375920910194566,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5313267425162138, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6375920910194566, 'final_confidence': 0.6375920910194566}"
med:pmid:39922597,med:pmid:39922597:sec:introduction:sent:4,enalapril,ACEi,sacubitril_valsartan,ARNi,"In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).",2025-02-08,,introduction,4,1,0.5313267425162138,observational study,1.2,0.6375920910194566,0.6375920910194566,"['combination', 'risk']","{""combination"": [""acei/arb/arni""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}, ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['relationship:combination', 'risk_terms', 'risk_posture:acknowledgment', 'claim_strength:confirmatory']",[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5313267425162138, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.6375920910194566, 'final_confidence': 0.6375920910194566}"
med:pmid:39888167,med:pmid:39888167:sec:conclusion:sent:6,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P < 0.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P < 0.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P = 0.002). Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations.",2025-01-30,,conclusion,6,1,0.522322840951098,other,1.0,0.522322840951098,0.522322840951098,"['compared with', 'cohort']","{""comparative_terms"": [""compared with""], ""study_context"": [""cohort""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.522322840951098, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.522322840951098, 'final_confidence': 0.522322840951098}"
med:pmid:39888167,med:pmid:39888167:sec:methods:sent:2,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States. This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.,2025-01-30,,methods,2,1,0.522322840951098,other,1.0,0.522322840951098,0.522322840951098,"['versus', 'cohort', 'retrospective']","{""comparative_terms"": [""versus""], ""study_context"": [""cohort"", ""retrospective""], ""real_world_terms"": [""retrospective""]}","['comparative_terms', 'study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.522322840951098, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.522322840951098, 'final_confidence': 0.522322840951098}"
med:pmid:39888167,med:pmid:39888167:sec:results:sent:3,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,The primary endpoint (all-cause hospitalization) and secondary endpoints were analysed in propensity score-matched cohorts. A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed.,2025-01-30,,results,3,1,0.522322840951098,other,1.0,0.522322840951098,0.522322840951098,['cohort'],"{""study_context"": [""cohort""], ""endpoint_terms"": [""primary endpoint""], ""claim_strength_terms"": {""suggestive"": [""secondary endpoints""]}}","['study_context', 'endpoint_terms', 'claim_strength:suggestive']",[],,,,[],evidence,clinical_context,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.522322840951098, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.522322840951098, 'final_confidence': 0.522322840951098}"
med:pmid:39864551,med:pmid:39864551:sec:conclusion:sent:9,enalapril,ACEi,sacubitril_valsartan,ARNI,"The most common adverse events were hypotension and elevated serum potassium levels, though these were minimal and did not require discontinuation of ARNI therapy. Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events.",2025-01-27,,conclusion,9,1,0.5193555758631001,other,1.0,0.5193555758631001,0.5193555758631001,"['superior', 'adverse events', 'risk', 'safety', 'safety profile', 'serious', 'serious adverse events']","{""comparative_terms"": [""superior""], ""risk_terms"": [""adverse events"", ""risk"", ""safety"", ""safety profile"", ""serious"", ""serious adverse events""], ""endpoint_terms"": [""blood pressure""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""], ""minimization"": [""minimal risk""], ""reassurance"": [""favorable safety profile""]}, ""claim_strength_terms"": {""exploratory"": [""promising""]}}","['comparative_terms', 'risk_terms', 'endpoint_terms', 'risk_posture:acknowledgment', 'risk_posture:minimization', 'risk_posture:reassurance', 'claim_strength:exploratory']",[],,,,[],comparative,comparative_safety,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5193555758631001, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5193555758631001, 'final_confidence': 0.5193555758631001}"
med:pmid:39829077,med:pmid:39829077:sec:methods:sent:5,enalapril,ACEis,sacubitril_valsartan,ARNis,"GDMT was defined by five medication classes-angiotensin-converting enzyme (ACE) inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is) and vasodilators (Black patients only).",2025-01-19,,methods,5,1,0.5115250198606409,other,1.0,0.5115250198606409,0.5115250198606409,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5115250198606409, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5115250198606409, 'final_confidence': 0.5115250198606409}"
med:pmid:39829077,med:pmid:39829077:sec:results:sent:8,enalapril,ACEis,sacubitril_valsartan,ARNis,"Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively.",2025-01-19,,results,8,1,0.5115250198606409,other,1.0,0.5115250198606409,0.5115250198606409,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5115250198606409, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5115250198606409, 'final_confidence': 0.5115250198606409}"
med:pmid:39829077,med:pmid:39829077:sec:results:sent:9,enalapril,ACEis,sacubitril_valsartan,ARNis,"Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at ≥80% of the target dose for ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively.",2025-01-19,,results,9,1,0.5115250198606409,other,1.0,0.5115250198606409,0.5115250198606409,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5115250198606409, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5115250198606409, 'final_confidence': 0.5115250198606409}"
ppr:doi:10.1101/2025.01.10.25320367,ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:8,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"The groups were well matched for age: 52.9±11.3 (IVB) vs. 53.5±11.8, gender: 57% male, HFrEF diagnosis: 66.4%, co-morbidities: hypertension 81.3% and coronary artery disease event 38.3%, and goal-directed medical therapy: ß-adrenergic blockers 89.7%, ACEi/ARB/sacubitril/valsartan 79.4%, mineral corticoid antagonists 39.3%.",2025-01-12,,results,8,1,0.5047701944854935,other,1.0,0.5047701944854935,0.5047701944854935,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.5047701944854935, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.5047701944854935, 'final_confidence': 0.5047701944854935}"
med:pmid:39792134,med:pmid:39792134:sec:introduction:sent:1,enalapril,ACEi,sacubitril_valsartan,sacubitril/valsartan,"Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.<h4>Methods and results</h4>This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status.",2025-01-10,,results,1,1,0.5028566797257031,randomized controlled trial,1.6,0.804570687561125,0.804570687561125,"['versus', 'safety', 'double-blind', 'randomized', 'randomized controlled trial', 'trial']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""double-blind"", ""randomized"", ""randomized controlled trial"", ""trial""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.728707+00:00,"{'recency_weight': 0.5028566797257031, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.804570687561125, 'final_confidence': 0.804570687561125}"
med:pmid:40463763,med:pmid:40463763:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,Angiotensin receptor-neprilysin inhibitor (ARNI) has superior beneficial effects on mortality and quality of life compared to angiotensin-converting enzyme inhibitor (ACEI).,2025-01-01,,introduction,2,1,0.494335233912211,other,1.0,0.494335233912211,0.494335233912211,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.494335233912211, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.494335233912211, 'final_confidence': 0.494335233912211}"
med:pmid:40463763,med:pmid:40463763:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,"The study was conducted to evaluate the possible impact of ARNI therapy compared to ACEI on cardiac remodeling using echocardiographic parameters, including global longitudinal strain (GLS) in heart failure with reduced left ventricular ejection fraction (HFrEF) patients. This prospective observational study included eighty recently diagnosed HFrEF patients with left ventricular ejection fraction (LVEF) ≤35%, prescribed the four pillars of guideline-directed medical therapy, and uptitrated to the maximally tolerated doses.",2025-01-01,,methods,4,1,0.494335233912211,other,1.0,0.494335233912211,0.494335233912211,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.494335233912211, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.494335233912211, 'final_confidence': 0.494335233912211}"
med:pmid:40463763,med:pmid:40463763:sec:methods:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI.",2025-01-01,,methods,5,1,0.494335233912211,other,1.0,0.494335233912211,0.494335233912211,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.494335233912211, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.494335233912211, 'final_confidence': 0.494335233912211}"
med:pmid:40463763,med:pmid:40463763:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group.",2025-01-01,,results,7,1,0.494335233912211,other,1.0,0.494335233912211,0.494335233912211,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""significant reduction""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.494335233912211, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.494335233912211, 'final_confidence': 0.494335233912211}"
med:pmid:40463763,med:pmid:40463763:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index.",2025-01-01,,results,8,1,0.494335233912211,other,1.0,0.494335233912211,0.494335233912211,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""significant improvement""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T12:24:15.744624+00:00,"{'recency_weight': 0.494335233912211, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.494335233912211, 'final_confidence': 0.494335233912211}"
med:pmid:39720381,med:pmid:39720381:sec:abstract:sent:6,enalapril,ACE inhibitors,sacubitril_valsartan,ARNIs,"Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations.",2024-11-23,,abstract,6,1,0.4581756213471096,review,0.9,0.41235805921239865,0.41235805921239865,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4581756213471096, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.41235805921239865, 'final_confidence': 0.41235805921239865}"
med:pmid:39563094,med:pmid:39563094:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.",2024-11-19,,conclusion,11,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],alternative,disfavored,favored,['preferred_over'],safety,safety_acknowledgment,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39563094,med:pmid:39563094:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.,2024-11-19,,results,10,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,"['versus', 'safety']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39563094,med:pmid:39563094:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.,2024-11-19,,results,3,1,0.4547084434124103,randomized controlled trial,1.6,0.7275335094598565,0.7275335094598565,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4547084434124103, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7275335094598565, 'final_confidence': 0.7275335094598565}"
med:pmid:39210725,med:pmid:39210725:sec:introduction:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Participants with chronic HF, New York Heart Association classes II through IV symptoms, and elevated natriuretic peptides were randomized to treatment with either sacubitril/valsartan or a renin-angiotensin system inhibitor (RASi)-enalapril in the PARADIGM-HF trial or valsartan in the PARAGON-HF trial.",2024-11-01,,introduction,5,1,0.4394279771444405,randomized controlled trial,1.6,0.7030847634311048,0.7030847634311048,"['randomized', 'trial']","{""study_context"": [""randomized"", ""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4394279771444405, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7030847634311048, 'final_confidence': 0.7030847634311048}"
med:pmid:39210725,med:pmid:39210725:sec:methods:sent:6,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan vs RASi (enalapril or valsartan).,2024-11-01,,methods,6,1,0.4394279771444405,randomized controlled trial,1.6,0.7030847634311048,0.7030847634311048,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4394279771444405, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.7030847634311048, 'final_confidence': 0.7030847634311048}"
med:pmid:39439294,med:pmid:39439294:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF ≤40% (PARADIGM-HF) or LVEF ≥45% (PARAGON-HF).",2024-10-22,,results,3,1,0.4311618300796596,randomized controlled trial,1.6,0.6898589281274554,0.6898589281274554,"['versus', 'randomized']","{""comparative_terms"": [""versus""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4311618300796596, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6898589281274554, 'final_confidence': 0.6898589281274554}"
med:pmid:39544776,med:pmid:39544776:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).,2024-10-15,,introduction,1,1,0.42546822222561836,other,1.0,0.42546822222561836,0.42546822222561836,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.42546822222561836, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.42546822222561836, 'final_confidence': 0.42546822222561836}"
med:pmid:39544776,med:pmid:39544776:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets.",2024-10-15,,methods,3,1,0.42546822222561836,other,1.0,0.42546822222561836,0.42546822222561836,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.42546822222561836, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.42546822222561836, 'final_confidence': 0.42546822222561836}"
med:pmid:38330576,med:pmid:38330576:sec:conclusion:sent:18,enalapril,enalapril,sacubitril_valsartan,Sacubitril valsartan,The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.,2024-10-01,,conclusion,18,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:38330576,med:pmid:38330576:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril valsartan,This study aimed to explore the clinical efficacy of sacubitril valsartan sodium and enalapril in such patients.,2024-10-01,,introduction,3,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:38330576,med:pmid:38330576:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril Valsartan,A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure.,2024-10-01,,introduction,0,1,0.4143055705373166,observational study,1.2,0.49716668464477987,0.49716668464477987,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4143055705373166, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.49716668464477987, 'final_confidence': 0.49716668464477987}"
med:pmid:39319469,med:pmid:39319469:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point.",2024-09-25,,conclusion,11,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).",2024-09-25,,introduction,3,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['versus', 'safety', 'double-blind', 'randomized', 'trial']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""double-blind"", ""randomized"", ""trial""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up.,2024-09-25,,methods,4,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['versus', 'safety', 'randomized']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""], ""study_context"": [""randomized""]}","['comparative_terms', 'risk_terms', 'study_context']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:methods:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain.",2024-09-25,,methods,5,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children.",2024-09-25,,results,10,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39319469,med:pmid:39319469:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188).",2024-09-25,,results,7,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:conclusion:sent:12,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.",2024-09-25,,conclusion,12,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:introduction:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,This study sought to examine the association between asymptomatic vs symptomatic hypotension and outcomes in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).,2024-09-25,,introduction,2,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In a post hoc analysis of PARADIGM-HF, the efficacy and safety of sacubitril/valsartan compared to enalapril were estimated using time-updated Cox proportional hazards models.",2024-09-25,,methods,3,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['compared to', 'safety']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""safety""], ""claim_strength_terms"": {""suggestive"": [""post hoc""]}}","['comparative_terms', 'risk_terms', 'claim_strength:suggestive']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.,2024-09-25,,results,10,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['vs', 'safety']","{""comparative_terms"": [""vs""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:11,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension.,2024-09-25,,results,11,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['vs', 'randomized']","{""comparative_terms"": [""vs""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39320292,med:pmid:39320292:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (P<sub>interaction</sub> = 0.01), and this was also true for cardiovascular and all-cause deaths.",2024-09-25,,results,9,1,0.4096116822453929,randomized controlled trial,1.6,0.6553786915926287,0.6553786915926287,"['compared to', 'vs']","{""comparative_terms"": [""compared to"", ""vs""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4096116822453929, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6553786915926287, 'final_confidence': 0.6553786915926287}"
med:pmid:39284545,med:pmid:39284545:sec:conclusion:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups.",2024-09-14,,conclusion,9,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes', 'risk']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes"", ""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF.",2024-09-14,,introduction,1,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['similar to', 'versus', 'trial']","{""comparative_terms"": [""similar to"", ""versus""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily.",2024-09-14,,methods,3,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['adverse events', 'aes']","{""risk_terms"": [""adverse events"", ""aes""], ""claim_strength_terms"": {""suggestive"": [""post-hoc""]}}","['risk_terms', 'claim_strength:suggestive']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Of 223 patients, 28.2 % experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95 % CI, 1.3-3.8; p = 0.0027).",2024-09-14,,results,4,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"However, reduction in mean systolic blood pressure from baseline to study end did not significantly differ (sacubitril/valsartan: -2.2 mmHg vs enalapril: -1.3 mmHg; p = 0.6895).",2024-09-14,,results,5,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4 % vs 6.9 %, p = 0.5957).",2024-09-14,,results,7,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'vs', 'aes']","{""comparative_terms"": [""versus"", ""vs""], ""risk_terms"": [""aes""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs.,2024-09-14,,results,8,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['versus', 'aes', 'risk']","{""comparative_terms"": [""versus""], ""risk_terms"": [""aes"", ""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39284545,med:pmid:39284545:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.,2024-09-14,,results,0,1,0.4011439046284056,randomized controlled trial,1.6,0.641830247405449,0.641830247405449,"['adverse events', 'risk']","{""risk_terms"": [""adverse events"", ""risk""]}",['risk_terms'],[],,,,[],safety,safety_acknowledgment,0.9,NEG,-3.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.4011439046284056, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.641830247405449, 'final_confidence': 0.641830247405449}"
med:pmid:39387766,med:pmid:39387766:sec:conclusion:sent:13,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).,2024-08-31,,conclusion,13,1,0.39061942959046086,randomized controlled trial,1.6,0.6249910873447374,0.6249910873447374,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.39061942959046086, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6249910873447374, 'final_confidence': 0.6249910873447374}"
med:pmid:39387766,med:pmid:39387766:sec:methods:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) were global, randomized clinical trials testing sacubitril/valsartan against a renin-angiotensin system inhibitor (RASi) (enalapril or valsartan, respectively) in patients with HF and left ventricular ejection fraction ≤40% (PARADIGM-HF) or left ventricular ejection fraction ≥45% (PARAGON-HF).",2024-08-31,,methods,3,1,0.39061942959046086,randomized controlled trial,1.6,0.6249910873447374,0.6249910873447374,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.39061942959046086, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.6249910873447374, 'final_confidence': 0.6249910873447374}"
med:pmid:39262640,med:pmid:39262640:sec:introduction:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNI,This study aimed to investigate the prevalence of influenza vaccination among Japanese patients with HF enrolled in the PARALLEL-HF (Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) trial and the association between receiving influenza vaccination and cardiovascular events including death or HF hospitalization.,2024-08-29,,introduction,2,1,0.38913864476570686,other,1.0,0.38913864476570686,0.38913864476570686,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.38913864476570686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.38913864476570686, 'final_confidence': 0.38913864476570686}"
med:pmid:39262640,med:pmid:39262640:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination.",2024-08-29,,results,3,1,0.38913864476570686,other,1.0,0.38913864476570686,0.38913864476570686,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.38913864476570686, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.38913864476570686, 'final_confidence': 0.38913864476570686}"
med:pmid:39111953,med:pmid:39111953:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.",2024-08-01,,abstract,3,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['vs', 'add-on therapy', 'phase', 'phase iv', 'randomized', 'trial']","{""comparative_terms"": [""vs""], ""add-on therapy"": [""added to""], ""study_context"": [""phase"", ""phase iv"", ""randomized"", ""trial""], ""trial_phase_terms"": [""phase iv""]}","['comparative_terms', 'relationship:add-on therapy', 'study_context', 'trial_phase_terms']",[],add_on,add_on,backbone,['add_on_to'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39111953,med:pmid:39111953:sec:abstract:sent:7,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).",2024-08-01,,abstract,7,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['compared with', 'safety']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:39111953,med:pmid:39111953:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.,2024-08-01,,title,0,1,0.36898749663138863,other,1.0,0.36898749663138863,0.36898749663138863,"['versus', 'trial']","{""comparative_terms"": [""versus""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.36898749663138863, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.36898749663138863, 'final_confidence': 0.36898749663138863}"
med:pmid:38904251,med:pmid:38904251:sec:results:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,"Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-Mortality in Patients With Chronic Heart Failure) clinical trials.",2024-06-21,,results,3,1,0.3413479679177815,randomized controlled trial,1.6,0.5461567486684504,0.5461567486684504,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.3413479679177815, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.5461567486684504, 'final_confidence': 0.5461567486684504}"
med:pmid:38663899,med:pmid:38663899:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril valsartan,We report a case in which bilateral renal artery revascularisation allowed the safe reintroduction of enalapril (and subsequently sacubitril valsartan) in a patient with severe left ventricular systolic dysfunction.,2024-04-24,,abstract,2,1,0.30574715062600727,case report,0.7,0.21402300543820507,0.21402300543820507,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.30574715062600727, 'study_type': 'case report', 'study_type_weight': 0.7, 'mention_count': 1, 'combined_weight': 0.21402300543820507, 'final_confidence': 0.21402300543820507}"
med:pmid:38597935,med:pmid:38597935:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) in patients with heart failure with reduced ejection fraction (HFrEF).,2024-04-10,,introduction,1,1,0.2977255199404633,review,0.9,0.267952967946417,0.267952967946417,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2977255199404633, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.267952967946417, 'final_confidence': 0.267952967946417}"
med:pmid:38588927,med:pmid:38588927:sec:methods:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) was a global randomized controlled trial evaluating sacubitril/valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF).,2024-04-06,,methods,4,1,0.2954725250074299,randomized controlled trial,1.6,0.4727560400118878,0.4727560400118878,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.2954725250074299, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4727560400118878, 'final_confidence': 0.4727560400118878}"
med:pmid:38508844,med:pmid:38508844:sec:conclusion:sent:15,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).",2024-03-01,,conclusion,15,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['versus', 'safety', 'tolerability']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety"", ""tolerability""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38508844,med:pmid:38508844:sec:introduction:sent:2,enalapril,Enalapril,sacubitril_valsartan,sacubitril/valsartan,Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.,2024-03-01,,results,2,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['versus', 'randomized', 'trial']","{""comparative_terms"": [""versus""], ""study_context"": [""randomized"", ""trial""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEG,-3.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38508844,med:pmid:38508844:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively).",2024-03-01,,methods,3,1,0.2759475063309733,randomized controlled trial,1.6,0.4415160101295573,0.4415160101295573,"['vs', 'double-blind', 'randomized']","{""comparative_terms"": [""vs""], ""study_context"": [""double-blind"", ""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.2759475063309733, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.4415160101295573, 'final_confidence': 0.4415160101295573}"
med:pmid:38356826,med:pmid:38356826:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In CHF patients, the combination of LBBP with sacubitril/valsartan had a better therapeutic effect compared to LBBP with enalapril, with more effective improvement of the cardiopulmonary function, reduction of myocardial injury, and improvement in quality of life.",2024-01-01,,conclusion,6,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,5.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,To assess the efficacy of left bundle branch pacing (LBBP) combined with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF).,2024-01-01,,introduction,1,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We divided the data into two treatment groups for the analysis: 71 patients received LBBP combined with sacubitril/valsartan treatment (sacubitril/valsartan group), and 67 received LBBP combined with enalapril treatment (enalapril group).",2024-01-01,,methods,3,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,['combination'],"{""combination"": [""combined with""]}",['relationship:combination'],[],add_on,add_on,add_on,['combination_with'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38356826,med:pmid:38356826:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.,2024-01-01,,methods,0,1,0.24623063833027797,other,1.0,0.24623063833027797,0.24623063833027797,"['observational', 'retrospective']","{""study_context"": [""observational"", ""retrospective""], ""real_world_terms"": [""observational"", ""retrospective""]}","['study_context', 'real_world_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.24623063833027797, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.24623063833027797, 'final_confidence': 0.24623063833027797}"
med:pmid:38764991,med:pmid:38764991:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,<b>Background:</b> The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to enalapril in patients with reduced ejection fraction (HFrEF).,2023-12-06,,abstract,2,1,0.23436829380924173,review,0.9,0.21093146442831756,0.21093146442831756,"['superior', 'trial']","{""comparative_terms"": [""superior""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],alternative,disfavored,favored,['preferred_over'],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.23436829380924173, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.21093146442831756, 'final_confidence': 0.21093146442831756}"
med:pmid:37989299,med:pmid:37989299:sec:conclusion:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The efficacy of sacubitril/valsartan compared with enalapril was consistent across baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.,2023-11-21,,conclusion,8,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,No significant difference was observed between sacubitril/valsartan and enalapril for the composite outcome of cardiovascular death and HF hospitalization across SBP tertiles (P-interaction=0.2682).,2023-11-21,,results,5,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,['no significant difference'],"{""comparative_terms"": [""no significant difference""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Although the P-interaction value was not significant (0.2106), a greater reduction in NT-proBNP with sacubitril/valsartan compared with enalapril was observed in patients with SBP >130 mmHg (P=0.0076).",2023-11-21,,results,6,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,['compared with'],"{""comparative_terms"": [""compared with""], ""claim_strength_terms"": {""confirmatory"": [""p=""], ""suggestive"": [""greater reduction""]}}","['comparative_terms', 'claim_strength:confirmatory', 'claim_strength:suggestive']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:37989299,med:pmid:37989299:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.",2023-11-21,,results,7,1,0.2277863851769027,randomized controlled trial,1.6,0.3644582162830443,0.3644582162830443,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.2277863851769027, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.3644582162830443, 'final_confidence': 0.3644582162830443}"
med:pmid:38084196,med:pmid:38084196:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan and enalapril in patients with heart failure.,2023-11-10,,abstract,1,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04).,2023-11-10,,results,6,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk', 'pooled analysis']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""study_context"": [""pooled analysis""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91).,2023-11-10,,results,7,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86).,2023-11-10,,results,8,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'risk']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.",2023-11-10,,results,9,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['compared to', 'superior', 'meta-analysis']","{""comparative_terms"": [""compared to"", ""superior""], ""study_context"": [""meta-analysis""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,evidence_review,0.7,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:38084196,med:pmid:38084196:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Comparison of Outcomes Between Sacubitril/Valsartan and Enalapril in Patients With Heart Failure: A Systematic Review and Meta-Analysis.,2023-11-10,,results,0,1,0.22307742657669394,review,0.9,0.20076968391902456,0.20076968391902456,"['meta-analysis', 'review', 'systematic review']","{""study_context"": [""meta-analysis"", ""review"", ""systematic review""]}",['study_context'],[],,,,[],evidence,evidence_review,0.7,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.713008+00:00,"{'recency_weight': 0.22307742657669394, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.20076968391902456, 'final_confidence': 0.20076968391902456}"
med:pmid:37941691,med:pmid:37941691:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril for chronic heart failure (CHF) with reduced ejection fraction (EF).",2023-09-27,,introduction,1,1,0.20519514378202022,other,1.0,0.20519514378202022,0.20519514378202022,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.20519514378202022, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.20519514378202022, 'final_confidence': 0.20519514378202022}"
med:pmid:37635080,med:pmid:37635080:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PARALLEL-HF study assessed the efficacy and safety of sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced ejection fraction (HFrEF).,2023-08-26,,introduction,1,1,0.19309694709725492,other,1.0,0.19309694709725492,0.19309694709725492,"['vs', 'safety']","{""comparative_terms"": [""vs""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19309694709725492, 'final_confidence': 0.19309694709725492}"
med:pmid:37635080,med:pmid:37635080:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"At OLE baseline, higher concentrations of B-type natriuretic peptide (BNP) and urine cGMP, and lower concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP), were observed in the sacubitril/valsartan core group (patients who received sacubitril/valsartan in both the core and extension study) than in the enalapril core group (patients who received enalapril in the core study and were then transitioned to sacubitril/valsartan).",2023-08-26,,results,7,1,0.19309694709725492,other,1.0,0.19309694709725492,0.19309694709725492,['switching'],"{""switching"": [""transitioned to""]}",['relationship:switching'],[],switch,switch_source,switch_destination,['switch_to'],positioning,switching,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.19309694709725492, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.19309694709725492, 'final_confidence': 0.19309694709725492}"
med:pmid:37240819,med:pmid:37240819:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril.,2023-05-12,,abstract,1,1,0.15788940853732833,other,1.0,0.15788940853732833,0.15788940853732833,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.15788940853732833, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15788940853732833, 'final_confidence': 0.15788940853732833}"
med:pmid:37104912,med:pmid:37104912:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,This study aimed to estimate the financial and economic impact of sacubitril/valsartan compared with enalapril for the treatment and prevention of hospitalization/rehospitalization because of heart failure with reduced ejection fraction (HFrEF).,2023-04-25,,introduction,1,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37104912,med:pmid:37104912:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In 5 years, the total cost of treating patients with HFrEF with sacubitril/valsartan at current market coverage and annual growth conditions is ₱15.430 billion, which is ₱11.077 billion higher than fully treating with enalapril only.",2023-04-25,,results,8,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,[],"{""access_terms"": [""coverage""]}",['access_terms'],[],,,,[],access,coverage_access,0.65,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37104912,med:pmid:37104912:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The total required additional investment with treatment of sacubitril/valsartan compared with the full enalapril arm are ₱407 million (at 30-day coverage), ₱800 million (at 60-day coverage), and ₱1.181 billion (at 90-day coverage).",2023-04-25,,results,9,1,0.15287357531300366,other,1.0,0.15287357531300366,0.15287357531300366,['compared with'],"{""comparative_terms"": [""compared with""], ""access_terms"": [""coverage""]}","['comparative_terms', 'access_terms']",[],,,,[],access,coverage_access,0.65,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.15287357531300366, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.15287357531300366, 'final_confidence': 0.15287357531300366}"
med:pmid:37043670,med:pmid:37043670:sec:abstract:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The results of this study show that sacubitril/valsartan can be used in patients with AMI instead of enalapril.,2023-04-12,,abstract,10,1,0.14914572391312025,other,1.0,0.14914572391312025,0.14914572391312025,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14914572391312025, 'final_confidence': 0.14914572391312025}"
med:pmid:37043670,med:pmid:37043670:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"This study focuses on the relevant indexes of VR in patients with AMI, in which, the intervention effects of sacubitril/valsartan and enalapril were compared, guiding the clinical treatment.",2023-04-12,,abstract,2,1,0.14914572391312025,other,1.0,0.14914572391312025,0.14914572391312025,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14914572391312025, 'final_confidence': 0.14914572391312025}"
med:pmid:37407154,med:pmid:37407154:sec:conclusion:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Irrespective of anemia status, sacubitril/valsartan compared with enalapril, decreased mortality and hospitalization.",2023-04-12,,conclusion,13,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:conclusion:sent:15,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure [PARADIGM-HF] trial; NCT01035255).,2023-04-12,,conclusion,15,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,The authors investigated whether concomitant neprilysin inhibition might ameliorate this effect of renin-angiotensin system blockers in PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure).,2023-04-12,,introduction,3,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients assigned to sacubitril/valsartan were less likely to develop anemia at 12 months (321 of 2,806 [11.4%]) compared with patients randomized to enalapril (440 of 2,824 [15.6%]) (OR: 0.70 [95% CI: 0.60-0.81]; P < 0.001).",2023-04-12,,results,10,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,"['compared with', 'randomized']","{""comparative_terms"": [""compared with""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan, compared with enalapril, decreased the risk of cardiovascular death or heart failure hospitalization similarly in patients with (HR: 0.84; 95% CI: 0.71-1.00) and without anemia (HR: 0.78 [95% CI: 0.71-0.87]; P value for interaction = 0.478).",2023-04-12,,results,8,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}, ""claim_strength_terms"": {""confirmatory"": [""p value""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37407154,med:pmid:37407154:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Between baseline and 12 months, hemoglobin decreased by 1.5 g/L (95% CI: 1.2-1.7 g/L) with sacubitril/valsartan compared with 2.3 g/L (95% CI: 2.0-2.6 g/L) with enalapril: mean difference 0.8 g/L (95% CI: 0.5-1.2 g/L; P < 0.001).",2023-04-12,,results,9,1,0.14914572391312025,randomized controlled trial,1.6,0.2386331582609924,0.2386331582609924,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14914572391312025, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.2386331582609924, 'final_confidence': 0.2386331582609924}"
med:pmid:37042870,med:pmid:37042870:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure.",2023-04-07,,abstract,3,1,0.14773626250371497,other,1.0,0.14773626250371497,0.14773626250371497,[],,[],[],add_on,add_on,backbone,['add_on_to'],,,,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.14773626250371497, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.14773626250371497, 'final_confidence': 0.14773626250371497}"
med:pmid:36812948,med:pmid:36812948:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF).",2023-02-20,,methods,4,1,0.13537830773627857,other,1.0,0.13537830773627857,0.13537830773627857,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.13537830773627857, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13537830773627857, 'final_confidence': 0.13537830773627857}"
med:pmid:36808581,med:pmid:36808581:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril.,2023-02-18,,introduction,1,1,0.13486510709004618,other,1.0,0.13486510709004618,0.13486510709004618,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.13486510709004618, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13486510709004618, 'final_confidence': 0.13486510709004618}"
med:pmid:36808581,med:pmid:36808581:sec:results:sent:13,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In Argentina the cost-per quality adjusted life-year (QALY) gained for sacubitril/valsartan versus enalapril was 391,158 ARS and 376,665 ARS for a social security and a private payer, respectively, at a 30- year horizon.",2023-02-18,,results,13,1,0.13486510709004618,other,1.0,0.13486510709004618,0.13486510709004618,['versus'],"{""comparative_terms"": [""versus""], ""access_terms"": [""payer""]}","['comparative_terms', 'access_terms']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.13486510709004618, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.13486510709004618, 'final_confidence': 0.13486510709004618}"
med:pmid:36943907,med:pmid:36943907:sec:conclusion:sent:9,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan increased the ucGMP/BNP ratio, compared with enalapril, and the effect of sacubitril/valsartan on clinical outcomes was not modified by baseline ucGMP/BNP ratio.",2023-01-25,,conclusion,9,1,0.12885635686155217,other,1.0,0.12885635686155217,0.12885635686155217,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12885635686155217, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12885635686155217, 'final_confidence': 0.12885635686155217}"
med:pmid:36943907,med:pmid:36943907:sec:methods:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We examined the relationship between ucGMP/BNP ratio and clinical outcomes, the effect of sacubitril/valsartan, compared with enalapril, on the ucGMP/BNP ratio, and the efficacy of sacubitril/valsartan on clinical outcomes according to baseline ucGMP/BNP ratio in PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).",2023-01-25,,methods,2,1,0.12885635686155217,other,1.0,0.12885635686155217,0.12885635686155217,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12885635686155217, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12885635686155217, 'final_confidence': 0.12885635686155217}"
med:pmid:36943907,med:pmid:36943907:sec:results:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Compared with baseline, the ucGMP/BNP ratio at 1 month and 8 months after randomization was higher with sacubitril/valsartan than with enalapril: ratio of geometric mean ratios at 1 month, 1.38 (95% CI, 1.27-1.51) and 8 months, 1.32 (95% CI, 1.20-1.45), and this difference was consistent across tertiles of ucGMP/BNP ratio at baseline (<i>P</i><sub>interaction</sub>=0.19 and 0.91, respectively).",2023-01-25,,results,6,1,0.12885635686155217,other,1.0,0.12885635686155217,0.12885635686155217,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12885635686155217, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12885635686155217, 'final_confidence': 0.12885635686155217}"
med:pmid:36943907,med:pmid:36943907:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The effect of sacubitril/valsartan, compared with enalapril, was consistent across tertiles of ucGMP/BNP ratio at baseline for all outcomes (<i>P</i><sub>interaction</sub> ≥0.31).",2023-01-25,,results,7,1,0.12885635686155217,other,1.0,0.12885635686155217,0.12885635686155217,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12885635686155217, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12885635686155217, 'final_confidence': 0.12885635686155217}"
med:pmid:36712243,med:pmid:36712243:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,"In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapril (an ACEI) in heart failure patients with reduced ejection fraction (HFrEF).",2023-01-13,,introduction,1,1,0.12595313216219373,other,1.0,0.12595313216219373,0.12595313216219373,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.12595313216219373, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12595313216219373, 'final_confidence': 0.12595313216219373}"
med:pmid:36712243,med:pmid:36712243:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"Since then, numerous new studies have provided further insight in HFrEF, sacubitril/valsartan can reduce N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, increase left ventricular ejection fraction (LVEF), reverse ventricular remodeling, and reduce other non-fatal manifestations of clinical deterioration as compared to ACEI/ARB.",2023-01-13,,introduction,3,1,0.12595313216219373,other,1.0,0.12595313216219373,0.12595313216219373,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.12595313216219373, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12595313216219373, 'final_confidence': 0.12595313216219373}"
med:pmid:36601956,med:pmid:36601956:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The study aimed to evaluate the pharmacokinetics and pharmacodynamics of single doses of sacubitril/valsartan (Part 1), and the efficacy and safety of sacubitril/valsartan versus enalapril administered twice daily for 52 weeks (Part 2) in pediatric patients with HF due to left ventricular systolic dysfunction with biventricular heart physiology.",2023-01-05,,methods,4,1,0.12405408052797928,randomized controlled trial,1.6,0.19848652884476686,0.19848652884476686,"['versus', 'safety']","{""comparative_terms"": [""versus""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12405408052797928, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.19848652884476686, 'final_confidence': 0.19848652884476686}"
med:pmid:36685156,med:pmid:36685156:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH).,2023-01-01,,introduction,1,1,0.12311531916513899,other,1.0,0.12311531916513899,0.12311531916513899,"['superior', 'risk']","{""comparative_terms"": [""superior""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],alternative,disfavored,favored,['preferred_over'],,,,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.12311531916513899, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.12311531916513899, 'final_confidence': 0.12311531916513899}"
med:pmid:36530836,med:pmid:36530836:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,<b><i>Background:</i></b> Post hoc analysis of the PARADIGM-HF trial showed that sacubitril/valsartan (S/V) was more effective than enalapril in lowering HbA1c in patients with heart failure and diabetes.,2022-11-18,,abstract,1,1,0.113246176475748,other,1.0,0.113246176475748,0.113246176475748,['trial'],"{""study_context"": [""trial""], ""endpoint_terms"": [""hba1c""], ""claim_strength_terms"": {""suggestive"": [""post hoc""]}}","['study_context', 'endpoint_terms', 'claim_strength:suggestive']",[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.113246176475748, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.113246176475748, 'final_confidence': 0.113246176475748}"
med:pmid:37143752,med:pmid:37143752:sec:conclusion:sent:13,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan is associated with better outcomes and may be cost-effective compared to enalapril for the management of HFrEF.,2022-10-01,,conclusion,13,1,0.10337988425526858,review,0.9,0.09304189582974172,0.09304189582974172,"['associated with better outcomes', 'compared to']","{""comparative_terms"": [""associated with better outcomes"", ""compared to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.10337988425526858, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.09304189582974172, 'final_confidence': 0.09304189582974172}"
med:pmid:37143752,med:pmid:37143752:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,To assess the cost-effectiveness of sacubitril/valsartan compared with enalapril in patients with heart failure with reduced ejection (HFrEF).,2022-10-01,,introduction,1,1,0.10337988425526858,review,0.9,0.09304189582974172,0.09304189582974172,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.10337988425526858, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.09304189582974172, 'final_confidence': 0.09304189582974172}"
med:pmid:37143752,med:pmid:37143752:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,All relevant full economic evaluation studies of sacubitril/valsartan versus enalapril for the treatment of patients with HFrEF were identified using ad hoc search strategies.,2022-10-01,,methods,3,1,0.10337988425526858,review,0.9,0.09304189582974172,0.09304189582974172,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.10337988425526858, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.09304189582974172, 'final_confidence': 0.09304189582974172}"
med:pmid:37143752,med:pmid:37143752:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review.,2022-10-01,,methods,0,1,0.10337988425526858,review,0.9,0.09304189582974172,0.09304189582974172,"['compared with', 'review', 'systematic review']","{""comparative_terms"": [""compared with""], ""study_context"": [""review"", ""systematic review""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.10337988425526858, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.09304189582974172, 'final_confidence': 0.09304189582974172}"
med:pmid:36132549,med:pmid:36132549:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"However, HFpEF patients that underwent ARNI treatment achieved better outcomes than did patients that underwent ACEI treatment.",2022-09-12,,results,7,1,0.09971626131306949,randomized controlled trial,1.6,0.15954601810091118,0.15954601810091118,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.09971626131306949, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.15954601810091118, 'final_confidence': 0.15954601810091118}"
med:pmid:36133814,med:pmid:36133814:sec:abstract:sent:9,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan has been commonly compared to enalapril in cost effectiveness analysis and has been found to be similar to that of SGLT2i but was not considered a cost-effective treatment for heart failure with reduced ejection fraction in Thailand and Singapore with the current economic evaluation evidences.,2022-09-05,,abstract,9,1,0.09839948128065606,review,0.9,0.08855953315259046,0.08855953315259046,"['compared to', 'similar to']","{""comparative_terms"": [""compared to"", ""similar to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.09839948128065606, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.08855953315259046, 'final_confidence': 0.08855953315259046}"
med:pmid:35874853,med:pmid:35874853:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril.,2022-07-01,,abstract,3,1,0.08680804745587616,other,1.0,0.08680804745587616,0.08680804745587616,['randomized'],"{""study_context"": [""randomized""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08680804745587616, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08680804745587616, 'final_confidence': 0.08680804745587616}"
med:pmid:35874853,med:pmid:35874853:sec:abstract:sent:9,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all <i>p</i> < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively.",2022-07-01,,abstract,9,1,0.08680804745587616,other,1.0,0.08680804745587616,0.08680804745587616,"['compared with', 'vs']","{""comparative_terms"": [""compared with"", ""vs""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08680804745587616, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08680804745587616, 'final_confidence': 0.08680804745587616}"
med:pmid:35874853,med:pmid:35874853:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.,2022-07-01,,title,0,1,0.08680804745587616,other,1.0,0.08680804745587616,0.08680804745587616,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08680804745587616, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08680804745587616, 'final_confidence': 0.08680804745587616}"
med:pmid:35761118,med:pmid:35761118:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Frail patients in randomised trials of sacubitril/valsartan, aliskiren, or enalapril had twice the risk of mortality (hazard ratio [HR] 2.09, 1.62-2.71) and hospitalisations (HR 1.82, 1.37-2.41) compared with robust patients, which may reflect responsiveness to medications and/or factors unrelated to medication use.",2022-06-28,,results,8,1,0.0863148994095375,review,0.9,0.07768340946858375,0.07768340946858375,"['compared with', 'risk', 'randomised']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""study_context"": [""randomised""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,-0.5,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0863148994095375, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.07768340946858375, 'final_confidence': 0.07768340946858375}"
med:pmid:35717169,med:pmid:35717169:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.",2022-06-18,,introduction,1,1,0.08469121660026911,other,1.0,0.08469121660026911,0.08469121660026911,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""], ""endpoint_terms"": [""hba1c""]}","['comparative_terms', 'study_context', 'endpoint_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08469121660026911, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08469121660026911, 'final_confidence': 0.08469121660026911}"
med:pmid:35717169,med:pmid:35717169:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Across the spectrum of LVEF, sacubitril/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63-0.89, P = 0.001), compared with enalapril or valsartan.",2022-06-18,,results,8,1,0.08469121660026911,other,1.0,0.08469121660026911,0.08469121660026911,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.39999999999999997,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08469121660026911, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08469121660026911, 'final_confidence': 0.08469121660026911}"
med:pmid:35702942,med:pmid:35702942:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,"The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all-cause mortality in patients with ambulatory heart failure and reduced ejection fraction (HFrEF), in particular when it is maximally up-titrated.",2022-06-15,,introduction,1,1,0.08421009406344793,other,1.0,0.08421009406344793,0.08421009406344793,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08421009406344793, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.08421009406344793, 'final_confidence': 0.08421009406344793}"
med:pmid:35560696,med:pmid:35560696:sec:results:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients in the EVALUATE-HF trial (n = 464) were randomized to sacubitril/valsartan or enalapril for 12 weeks, followed by 12-week open-label sacubitril/valsartan.",2022-05-30,,results,3,1,0.08168989108733514,randomized controlled trial,1.6,0.13070382573973624,0.13070382573973624,"['randomized', 'trial']","{""study_context"": [""randomized"", ""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.08168989108733514, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.13070382573973624, 'final_confidence': 0.13070382573973624}"
med:pmid:35483448,med:pmid:35483448:sec:conclusion:sent:12,enalapril,ACEI,sacubitril_valsartan,ARNI,The ARNI study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to ACEI group.,2022-04-26,,conclusion,12,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,"['compared to', 'safety']","{""comparative_terms"": [""compared to""], ""risk_terms"": [""safety""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,POS,3.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,To compare the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up.,2022-04-26,,introduction,1,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,['safety'],"{""risk_terms"": [""safety""]}",['risk_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:methods:sent:3,enalapril,enalapril,sacubitril_valsartan,ARNI,Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI).,2022-04-26,,methods,3,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:results:sent:10,enalapril,ACEI,sacubitril_valsartan,ARNI,Readmission for heart failure were seen significantly higher in ACEI group than ARNI group (p value = 0.001).,2022-04-26,,results,10,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,[],"{""claim_strength_terms"": {""confirmatory"": [""p value""]}}",['claim_strength:confirmatory'],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:results:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,"A total of 200 patients were included in the present study, 100 each in ARNI and ACEI group.",2022-04-26,,results,7,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:results:sent:8,enalapril,ACEI,sacubitril_valsartan,ARNI,"The mean age of the population was 61.2 ± 8.4 years and 62.6 ± 8.6 years in ARNI group and ACEI group, respectively.",2022-04-26,,results,8,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:results:sent:9,enalapril,ACEI,sacubitril_valsartan,ARNI,The mean maximum tolerated dose by population in ARNI group was 203.6 mg and 8.9 mg in ACEI group.,2022-04-26,,results,9,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35483448,med:pmid:35483448:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,ARNI,Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.,2022-04-26,,results,0,1,0.0765820815824061,observational study,1.2,0.09189849789888732,0.09189849789888732,"['vs', 'safety', 'observational']","{""comparative_terms"": [""vs""], ""risk_terms"": [""safety""], ""study_context"": [""observational""], ""real_world_terms"": [""observational"", ""observational study""]}","['comparative_terms', 'risk_terms', 'study_context', 'real_world_terms']",[],,,,[],evidence,real_world,0.72,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.0765820815824061, 'study_type': 'observational study', 'study_type_weight': 1.2, 'mention_count': 1, 'combined_weight': 0.09189849789888732, 'final_confidence': 0.09189849789888732}"
med:pmid:35469709,med:pmid:35469709:sec:abstract:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enalapril on the reduction of cardiovascular (CV) mortality and heart failure hospitalizations rates.,2022-04-22,,abstract,4,1,0.07600255772499268,review,0.9,0.06840230195249342,0.06840230195249342,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.07600255772499268, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.06840230195249342, 'final_confidence': 0.06840230195249342}"
med:pmid:35343504,med:pmid:35343504:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction.,2022-03-01,,abstract,2,1,0.06885599251786198,other,1.0,0.06885599251786198,0.06885599251786198,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06885599251786198, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06885599251786198, 'final_confidence': 0.06885599251786198}"
med:pmid:35222898,med:pmid:35222898:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril valsartan,"Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases.",2022-02-18,,introduction,2,1,0.06743255354502309,randomized controlled trial,1.6,0.10789208567203695,0.10789208567203695,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06743255354502309, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.10789208567203695, 'final_confidence': 0.10789208567203695}"
med:pmid:35200707,med:pmid:35200707:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014.",2022-02-10,,abstract,1,1,0.06641584281452674,review,0.9,0.05977425853307407,0.05977425853307407,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06641584281452674, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.05977425853307407, 'final_confidence': 0.05977425853307407}"
med:pmid:33119090,med:pmid:33119090:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes.",2022-02-01,,introduction,1,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,['compared to'],"{""comparative_terms"": [""compared to""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNIs,"For patients with heart failure (HF), the effect of angiotensin receptor-neprilysin inhibitors (ARNIs, sacubitril/valsartan) on cardiac remodeling has been found to be superior to angiotensin-converting enzyme inhibitors (ACEI).",2022-02-01,,introduction,1,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:methods:sent:4,enalapril,enalapril,sacubitril_valsartan,ARNI,All patients received standard STEMI management and were divided into 2 groups (ARNI/enalapril).,2022-02-01,,methods,4,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,ARNI,"Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102].",2022-02-01,,results,10,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:results:sent:11,enalapril,enalapril,sacubitril_valsartan,ARNI,"The incidence of outpatient HF or HF hospitalization in the ARNI group was significantly lower than that in the enalapril group (HR, 0.36; 95% CI: 0.14 to 0.94; P=0.037).",2022-02-01,,results,11,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,[],"{""claim_strength_terms"": {""confirmatory"": [""p=""]}}",['claim_strength:confirmatory'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,ARNI,"We found that NT-proBNP concentration decreased more in the ARNI group than in the enalapril group [4 weeks: ratio of ARNI <i>vs.</i> enalapril 0.36, 95% confidence interval (CI): 0.24 to 0.52, P<0.001; 12 weeks: 0.54, 95% CI: 0.35 to 0.79, P<0.001; 24 weeks: 0.53, 95% CI: 0.32 to 0.83, P<0.001).",2022-02-01,,results,8,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,['vs'],"{""comparative_terms"": [""vs""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.39999999999999997,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35282662,med:pmid:35282662:sec:results:sent:9,enalapril,enalapril,sacubitril_valsartan,ARNI,"When compared to the enalapril group, the ARNI group patients had a significant reduction in LVEDV (P<0.001) and LVESV (P<0.001), and an improvement in LVEF (P=0.011) at 24 weeks.",2022-02-01,,results,9,1,0.06529035511888727,other,1.0,0.06529035511888727,0.06529035511888727,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""confirmatory"": [""p<"", ""p="", ""significant reduction""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6,POS,2.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06529035511888727, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06529035511888727, 'final_confidence': 0.06529035511888727}"
med:pmid:35081164,med:pmid:35081164:sec:conclusion:sent:11,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan was similar to either enalapril or valsartan in preventing the occurrence of AF in patients with HF.,2022-01-26,,conclusion,11,1,0.06455064593981291,review,0.9,0.05809558134583162,0.05809558134583162,['similar to'],"{""comparative_terms"": [""similar to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06455064593981291, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.05809558134583162, 'final_confidence': 0.05809558134583162}"
med:pmid:35081164,med:pmid:35081164:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"There was no significant difference in the prevention of AF occurrence between the sacubitril/valsartan group and the control group (enalapril or valsartan) in patients with HF (RR 1.07, 95%CI 0.95 to 1.19; I2 4%).",2022-01-26,,results,10,1,0.06455064593981291,review,0.9,0.05809558134583162,0.05809558134583162,['no significant difference'],"{""comparative_terms"": [""no significant difference""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06455064593981291, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.05809558134583162, 'final_confidence': 0.05809558134583162}"
med:pmid:34969175,med:pmid:34969175:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.",2022-01-19,,introduction,3,1,0.06369823731023073,randomized controlled trial,1.6,0.10191717969636918,0.10191717969636918,['compared to'],"{""comparative_terms"": [""compared to""], ""claim_strength_terms"": {""suggestive"": [""post hoc""]}}","['comparative_terms', 'claim_strength:suggestive']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06369823731023073, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.10191717969636918, 'final_confidence': 0.10191717969636918}"
med:pmid:34969175,med:pmid:34969175:sec:results:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p = 0.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p = 0.025).",2022-01-19,,results,10,1,0.06369823731023073,randomized controlled trial,1.6,0.10191717969636918,0.10191717969636918,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06369823731023073, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.10191717969636918, 'final_confidence': 0.10191717969636918}"
med:pmid:34989105,med:pmid:34989105:sec:conclusion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In patients with heart failure, sacubitril/valsartan reduced the risk of serious adverse renal outcomes and slowed decline in eGFR, compared with valsartan or enalapril, independent of baseline renal function.",2022-01-18,,conclusion,10,1,0.0635773870175676,other,1.0,0.0635773870175676,0.0635773870175676,"['compared with', 'risk', 'serious']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk"", ""serious""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_safety,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0635773870175676, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0635773870175676, 'final_confidence': 0.0635773870175676}"
med:pmid:34989105,med:pmid:34989105:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope.",2022-01-18,,results,4,1,0.0635773870175676,other,1.0,0.0635773870175676,0.0635773870175676,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.0635773870175676, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0635773870175676, 'final_confidence': 0.0635773870175676}"
med:pmid:34989105,med:pmid:34989105:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42-0.75; p < 0.001).",2022-01-18,,results,7,1,0.0635773870175676,other,1.0,0.0635773870175676,0.0635773870175676,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0635773870175676, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0635773870175676, 'final_confidence': 0.0635773870175676}"
med:pmid:34989105,med:pmid:34989105:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The mean eGFR change was -1.8 (95% CI -1.9 to -1.7) ml/min/1.73 m<sup>2</sup> /year for the sacubitril/valsartan group, compared with -2.4 (95% CI -2.5 to -2.2) ml/min/1.73 m<sup>2</sup> /year for the valsartan or enalapril group.",2022-01-18,,results,8,1,0.0635773870175676,other,1.0,0.0635773870175676,0.0635773870175676,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0635773870175676, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0635773870175676, 'final_confidence': 0.0635773870175676}"
med:pmid:35115085,med:pmid:35115085:sec:conclusion:sent:12,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction [EVALUATE-HF]; NCT02874794) (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).",2022-01-12,,conclusion,12,1,0.06285708496571288,other,1.0,0.06285708496571288,0.06285708496571288,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.06285708496571288, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06285708496571288, 'final_confidence': 0.06285708496571288}"
med:pmid:35115085,med:pmid:35115085:sec:methods:sent:3,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,"In an individual patient analysis from the EVALUATE-HF (Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction) (n = 221) and the PROVE-HF (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes) (n = 146) studies, we examined changes in BNP, N-terminal pro-BNP (NT-proBNP), and urinary cyclic guanosine monophosphate (ucGMP) from baseline to week 4 and week 12.",2022-01-12,,methods,3,1,0.06285708496571288,other,1.0,0.06285708496571288,0.06285708496571288,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.06285708496571288, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.06285708496571288, 'final_confidence': 0.06285708496571288}"
med:pmid:35035857,med:pmid:35035857:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Studies have shown sacubitril/valsartan can further reduce the risk of cardiovascular death or hospitalization for heart failure by 20% compared with enalapril.,2022-01-05,,abstract,2,1,0.06202704026398966,review,0.9,0.0558243362375907,0.0558243362375907,"['compared with', 'risk']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'risk_posture:acknowledgment']",[],,,,[],,,,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.06202704026398966, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0558243362375907, 'final_confidence': 0.0558243362375907}"
med:pmid:35400328,med:pmid:35400328:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan has revealed superior glycemic and blood pressure control compared with enalapril and irbesartan in patients with heart failure and type 2 diabetes and in individuals with chronic kidney disease.,2022-01-01,,introduction,1,1,0.061557659582569486,other,1.0,0.061557659582569486,0.061557659582569486,"['compared with', 'superior']","{""comparative_terms"": [""compared with"", ""superior""], ""endpoint_terms"": [""blood pressure""]}","['comparative_terms', 'endpoint_terms']","['chronic kidney disease', 'type 2 diabetes']",,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.697256+00:00,"{'recency_weight': 0.061557659582569486, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.061557659582569486, 'final_confidence': 0.061557659582569486}"
med:pmid:28024961,med:pmid:28024961:sec:introduction:sent:3,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan.<h4>Methods and design</h4>This is a multicenter, randomized, double-blind, parallel-group, active controlled study of 220 Japanese HFrEF patients.",2016-12-24,,introduction,3,1,0.0018946727266417542,randomized controlled trial,1.6,0.003031476362626807,0.003031476362626807,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.0018946727266417542, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.003031476362626807, 'final_confidence': 0.003031476362626807}"
med:pmid:28292483,med:pmid:28292483:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Unless priced lower than enalapril (<€0.045 per day), sacubitril/valsartan is very unlikely to be cost-saving/dominant.",2016-12-22,,conclusion,6,1,0.0018874902815072972,other,1.0,0.0018874902815072972,0.0018874902815072972,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018874902815072972, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0018874902815072972, 'final_confidence': 0.0018874902815072972}"
med:pmid:28292483,med:pmid:28292483:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction.<h4>Objectives</h4>To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial.<h4>Methods</h4>To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial.",2016-12-22,,introduction,1,1,0.0018874902815072972,other,1.0,0.0018874902815072972,0.0018874902815072972,"['compared with', 'superior', 'trial']","{""comparative_terms"": [""compared with"", ""superior""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],alternative,disfavored,favored,['preferred_over'],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018874902815072972, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0018874902815072972, 'final_confidence': 0.0018874902815072972}"
med:pmid:27804100,med:pmid:27804100:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"A 63-year-old woman previously stable on a regimen of atorvastatin 40 mg daily, carvedilol 25 mg twice daily, digoxin 0.125 mg daily, furosemide 40 mg daily, spironolactone 25 mg daily, rivaroxaban 15 mg daily, and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril/valsartan (Entresto™) started.",2016-12-01,,abstract,1,1,0.0018136989023797457,other,1.0,0.0018136989023797457,0.0018136989023797457,[],,[],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018136989023797457, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0018136989023797457, 'final_confidence': 0.0018136989023797457}"
med:pmid:27908347,med:pmid:27908347:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Treatment with sacubitril/valsartan was nearly twice as likely as enalapril to reduce NT-proBNP to values ≤1,000 pg/ml. (",2016-12-01,,conclusion,6,1,0.0018136989023797457,randomized controlled trial,1.6,0.0029019182438075933,0.0029019182438075933,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018136989023797457, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0029019182438075933, 'final_confidence': 0.0029019182438075933}"
med:pmid:27908347,med:pmid:27908347:sec:conclusion:sent:7,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.).,2016-12-01,,conclusion,7,1,0.0018136989023797457,randomized controlled trial,1.6,0.0029019182438075933,0.0029019182438075933,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.49999999999999994,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018136989023797457, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0029019182438075933, 'final_confidence': 0.0029019182438075933}"
med:pmid:27908347,med:pmid:27908347:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is unclear.<h4>Objectives</h4>The authors assessed whether a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were dependent on assigned treatment.<h4>Methods</h4>In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1 and 8 months.",2016-12-01,,introduction,1,1,0.0018136989023797457,randomized controlled trial,1.6,0.0029019182438075933,0.0029019182438075933,['trial'],"{""study_context"": [""trial""], ""endpoint_terms"": [""primary endpoint""]}","['study_context', 'endpoint_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018136989023797457, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0029019182438075933, 'final_confidence': 0.0029019182438075933}"
med:pmid:27908347,med:pmid:27908347:sec:results:sent:4,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomization than in enalapril-treated patients, and it fell to ≤1,000 pg/ml in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively.",2016-12-01,,results,4,1,0.0018136989023797457,randomized controlled trial,1.6,0.0029019182438075933,0.0029019182438075933,['versus'],"{""comparative_terms"": [""versus""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0018136989023797457, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0029019182438075933, 'final_confidence': 0.0029019182438075933}"
med:pmid:27868321,med:pmid:27868321:sec:conclusion:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The rates of dementia-related AEs in both treatment groups in PARADIGM-HF were similar to those in three other recent trials in HFrEF. We found no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related AEs, although longer follow-up may be necessary to detect such a signal and more sensitive tools are needed to detect lesser degrees of cognitive impairment.",2016-11-20,,conclusion,10,1,0.001776204857079728,randomized controlled trial,1.6,0.002841927771327565,0.002841927771327565,"['compared with', 'similar to', 'aes']","{""comparative_terms"": [""compared with"", ""similar to""], ""risk_terms"": [""aes""], ""claim_strength_terms"": {""suggestive"": [""signal""]}}","['comparative_terms', 'risk_terms', 'claim_strength:suggestive']",[],,,,[],safety,safety_acknowledgment,0.9,NEU,0.5,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001776204857079728, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002841927771327565, 'final_confidence': 0.002841927771327565}"
med:pmid:27868321,med:pmid:27868321:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,"Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril.",2016-11-20,,introduction,1,1,0.001776204857079728,randomized controlled trial,1.6,0.002841927771327565,0.002841927771327565,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001776204857079728, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002841927771327565, 'final_confidence': 0.002841927771327565}"
med:pmid:27868321,med:pmid:27868321:sec:results:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The narrow SMQ search identified 27 dementia-related AEs: 15 (0.36%) on enalapril and 12 (0.29%) on sacubitril/valsartan [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.33-1.59].",2016-11-20,,results,8,1,0.001776204857079728,randomized controlled trial,1.6,0.002841927771327565,0.002841927771327565,['aes'],"{""risk_terms"": [""aes""]}",['risk_terms'],[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001776204857079728, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002841927771327565, 'final_confidence': 0.002841927771327565}"
med:pmid:27747488,med:pmid:27747488:sec:abstract:sent:2,enalapril,ACEi,sacubitril_valsartan,ARNi,"In the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial of 8399 subjects with HFrEF, treatment with the ARNi LCZ696 (sacubitril/valsartan) was associated with statistically important reductions in cardiovascular death, all-cause mortality, and the composite of cardiovascular death or heart failure hospitalization in comparison with enalapril.",2016-11-01,,abstract,2,1,0.0017132589086360768,review,0.9,0.0015419330177724691,0.0015419330177724691,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0017132589086360768, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0015419330177724691, 'final_confidence': 0.0015419330177724691}"
med:pmid:28905031,med:pmid:28905031:sec:abstract:sent:6,enalapril,ACE inhibitor,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan may be used instead of an ACE inhibitor or ARB in patients with chronic symptomatic HFrEF class II or III to further reduce morbidity and mortality.,2016-10-17,,abstract,6,1,0.0016651444072378562,other,1.0,0.0016651444072378562,0.0016651444072378562,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0016651444072378562, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0016651444072378562, 'final_confidence': 0.0016651444072378562}"
med:pmid:27092662,med:pmid:27092662:sec:abstract:sent:5,enalapril,ACEI,sacubitril_valsartan,ARNI,"With the published results of the landmark trial Prospective comparison of ARNI with ACEI to Determine the Impact on Global Mortality and morbidity in HF (PARADIGM-HF), a new direction in the treatment of HF is anticipated.",2016-09-01,,abstract,5,1,0.0015258571468377382,review,0.9,0.0013732714321539644,0.0013732714321539644,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0013732714321539644, 'final_confidence': 0.0013732714321539644}"
med:pmid:27438344,med:pmid:27438344:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"<h4>Importance</h4>The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.",2016-09-01,,abstract,1,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:introduction:sent:10,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Sensitivity analyses demonstrated sacubitril/valsartan would remain cost-effective vs enalapril.,2016-09-01,,introduction,10,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:introduction:sent:2,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,"Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced ejection fraction in the United States and cost has been suggested as 1 factor that will influence the use of this agent. To estimate the cost-effectiveness of sacubitril/valsartan vs enalapril in the United States.<h4>Design, setting, and participants</h4>Data from US adults (mean [SD] age, 63.8 [11.5] years) with HF with reduced ejection fraction and characteristics similar to those in the PARADIGM-HF trial were used as inputs for a 2-state Markov model simulated HF.",2016-09-01,,introduction,2,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,"['similar to', 'vs', 'trial']","{""comparative_terms"": [""similar to"", ""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:introduction:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Hospital costs combined Medicare and private insurance reimbursement rates; medication costs included the wholesale acquisition cost for sacubitril/valsartan and enalapril.,2016-09-01,,introduction,5,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,[],"{""access_terms"": [""reimbursement""]}",['access_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:introduction:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Sensitivity analyses were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality-of-life estimates.<h4>Main outcomes and measures</h4>Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained.<h4>Results</h4>The 2-state Markov model of US adult patients (mean age, 63.8 years) calculated that there would be 220 fewer hospital admissions per 1000 patients with HF treated with sacubitril/valsartan vs enalapril over 30 years.",2016-09-01,,introduction,7,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:introduction:sent:8,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The incremental costs and QALYs gained with sacubitril/valsartan treatment were estimated at $35 512 and 0.78, respectively, compared with enalapril, equating to an incremental cost-effectiveness ratio (ICER) of $45 017 per QALY for the base-case.",2016-09-01,,introduction,8,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27438344,med:pmid:27438344:sec:title:sent:0,enalapril,Enalapril,sacubitril_valsartan,Sacubitril/Valsartan,Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.,2016-09-01,,introduction,0,1,0.0015258571468377382,other,1.0,0.0015258571468377382,0.0015258571468377382,['vs'],"{""comparative_terms"": [""vs""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0015258571468377382, 'final_confidence': 0.0015258571468377382}"
med:pmid:27618854,med:pmid:27618854:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitorenalapril in patients with heart failure and reduced ejection fraction.",2016-09-01,,introduction,1,1,0.0015258571468377382,randomized controlled trial,1.6,0.0024413714349403814,0.0024413714349403814,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.0015258571468377382, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0024413714349403814, 'final_confidence': 0.0024413714349403814}"
med:pmid:27618854,med:pmid:27618854:sec:results:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval,0.73-0.87;P<0.001) and for cardiovascular death was0.80 (0.71-0.89;P<0.001).",2016-09-01,,results,7,1,0.0015258571468377382,randomized controlled trial,1.6,0.0024413714349403814,0.0024413714349403814,['versus'],"{""comparative_terms"": [""versus""], ""claim_strength_terms"": {""confirmatory"": [""p<""]}}","['comparative_terms', 'claim_strength:confirmatory']",[],,,,[],comparative,comparative_efficacy,0.6000000000000001,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0024413714349403814, 'final_confidence': 0.0024413714349403814}"
med:pmid:27618854,med:pmid:27618854:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.,2016-09-01,,results,0,1,0.0015258571468377382,randomized controlled trial,1.6,0.0024413714349403814,0.0024413714349403814,"['add-on therapy', 'trial']","{""add-on therapy"": [""background therapy""], ""study_context"": [""trial""]}","['relationship:add-on therapy', 'study_context']",[],add_on,add_on,add_on,['combination_with'],positioning,combination,0.6499999999999999,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0015258571468377382, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0024413714349403814, 'final_confidence': 0.0024413714349403814}"
med:pmid:27573608,med:pmid:27573608:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan resulted in 20% reduction in the incidence rate of death or HF hospitalization compared to enalapril in symptomatic HFrEF patients in the seminal PARADIGM-HF trial.,2016-08-23,,abstract,2,1,0.001499999860815406,other,1.0,0.001499999860815406,0.001499999860815406,"['compared to', 'trial']","{""comparative_terms"": [""compared to""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001499999860815406, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.001499999860815406, 'final_confidence': 0.001499999860815406}"
med:pmid:27510447,med:pmid:27510447:sec:abstract:sent:6,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"Accordingly, both the new US and European Society of Cardiology heart failure guidelines recommend sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in patients with chronic heart failure who are currently receiving an ACE inhibitor or ARB.",2016-08-10,,abstract,6,1,0.0014634220770518187,review,0.9,0.0013170798693466369,0.0013170798693466369,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0014634220770518187, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0013170798693466369, 'final_confidence': 0.0013170798693466369}"
med:pmid:27395349,med:pmid:27395349:sec:conclusion:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Despite the increased risk associated with more recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect to cardiovascular or all-cause mortality. Patients with recent HF decompensation requiring hospitalization were more likely to experience cardiovascular death or HF hospitalization than those who had never been hospitalized.",2016-07-06,,conclusion,2,1,0.001369316093662767,randomized controlled trial,1.6,0.002190905749860427,0.002190905749860427,['risk'],"{""risk_terms"": [""risk""], ""endpoint_terms"": [""primary endpoint""], ""risk_posture_terms"": {""acknowledgment"": [""increased risk""]}}","['risk_terms', 'endpoint_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.001369316093662767, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002190905749860427, 'final_confidence': 0.002190905749860427}"
med:pmid:27395349,med:pmid:27395349:sec:conclusion:sent:4,enalapril,ACEI,sacubitril_valsartan,ARNI,Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).,2016-07-06,,conclusion,4,1,0.001369316093662767,randomized controlled trial,1.6,0.002190905749860427,0.002190905749860427,[],,[],[],,,,[],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.001369316093662767, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002190905749860427, 'final_confidence': 0.002190905749860427}"
med:pmid:27395349,med:pmid:27395349:sec:introduction:sent:1,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,"This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability.<h4>Background</h4>Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should be delayed until occurrence of clinical decompensation.<h4>Methods</h4>Outcomes were compared among patients who had prior hospitalization within 3 months of screening (n = 1,611 [19%]), between 3 and 6 months (n = 1,009 [12%]), between 6 and 12 months (n = 886 [11%]), >12 months (n = 1,746 [21%]), or who had never been hospitalized (n = 3,125 [37%]).<h4>Results</h4>Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular death or heart failure (HF) hospitalization during the course of the trial.",2016-07-06,,introduction,1,1,0.001369316093662767,randomized controlled trial,1.6,0.002190905749860427,0.002190905749860427,"['switching', 'trial']","{""switching"": [""switching from""], ""study_context"": [""trial""], ""endpoint_terms"": [""primary endpoint""]}","['relationship:switching', 'study_context', 'endpoint_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001369316093662767, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.002190905749860427, 'final_confidence': 0.002190905749860427}"
med:pmid:27417000,med:pmid:27417000:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization.<h4>Objectives</h4>This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital readmission at 30-days following HF hospitalization compared with enalapril.<h4>Methods</h4>We assessed the risk of 30-day readmission for any cause following investigator-reported hospitalizations for HF in the PARADIGM-HF trial, which randomized 8,399 participants with HF and reduced ejection fraction to treatment with LCZ696 or enalapril.<h4>Results</h4>Accounting for multiple hospitalizations per patient, there were 2,383 investigator-reported HF hospitalizations, of which 1,076 (45.2%) occurred in subjects assigned to LCZ696 and 1,307 (54.8%) occurred in subjects assigned to enalapril.",2016-07-01,,introduction,1,1,0.0013563757414980647,randomized controlled trial,1.6,0.0021702011863969036,0.0021702011863969036,"['compared with', 'risk', 'randomized', 'trial']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""study_context"": [""randomized"", ""trial""], ""risk_posture_terms"": {""acknowledgment"": [""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'risk_posture:acknowledgment']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.0013563757414980647, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0021702011863969036, 'final_confidence': 0.0021702011863969036}"
med:pmid:27334058,med:pmid:27334058:sec:abstract:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNi,"A recent clinical study indicated that an angiotensin II (Ang II) type 1 (AT<sub>1</sub>) receptor-neprilysin inhibitor (ARNi) designated LCZ696 (sacubitril/valsartan, as combined sodium complex) was superior to enalapril at reducing the risks of death and hospitalization due to heart failure.",2016-06-23,,abstract,1,1,0.0013359250585790908,other,1.0,0.0013359250585790908,0.0013359250585790908,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0013359250585790908, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.0013359250585790908, 'final_confidence': 0.0013359250585790908}"
med:pmid:27283779,med:pmid:27283779:sec:conclusion:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"However, the treatment benefit of sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70-0.93, P < 0.001) to that observed in patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71-0.88, P < 0.001). In PARADIGM-HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event.",2016-06-10,,conclusion,5,1,0.0013033482702782557,randomized controlled trial,1.6,0.0020853572324452093,0.0020853572324452093,['risk'],"{""risk_terms"": [""risk""], ""risk_posture_terms"": {""acknowledgment"": [""higher risk"", ""risk of""]}}","['risk_terms', 'risk_posture:acknowledgment']",[],,,,[],safety,safety_acknowledgment,0.9,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0013033482702782557, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020853572324452093, 'final_confidence': 0.0020853572324452093}"
med:pmid:27283779,med:pmid:27283779:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of enalapril was similar to that of patients who remained on target doses of both drugs.,2016-06-10,,conclusion,6,1,0.0013033482702782557,randomized controlled trial,1.6,0.0020853572324452093,0.0020853572324452093,['similar to'],"{""comparative_terms"": [""similar to""]}",['comparative_terms'],[],,,,[],comparative,comparative_efficacy,0.8,POS,1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0013033482702782557, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020853572324452093, 'final_confidence': 0.0020853572324452093}"
med:pmid:27283779,med:pmid:27283779:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril.<h4>Methods and results</h4>In a post-hoc analysis from PARADIGM-HF, we characterized patients by whether they received the maximal dose (200 mg sacubitril/valsartan or 10 mg enalapril twice daily) throughout the trial or had any dose reduction to lower doses (100/50/0 mg sacubitril/valsartan or 5/2.5/0 mg enalapril twice daily).",2016-06-10,,results,1,1,0.0013033482702782557,randomized controlled trial,1.6,0.0020853572324452093,0.0020853572324452093,['trial'],"{""study_context"": [""trial""], ""claim_strength_terms"": {""suggestive"": [""post-hoc""]}}","['study_context', 'claim_strength:suggestive']",[],,,,[],evidence,clinical_trial,0.7,POS,3.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0013033482702782557, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020853572324452093, 'final_confidence': 0.0020853572324452093}"
med:pmid:27283779,med:pmid:27283779:sec:introduction:sent:3,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In the two treatment arms, participants with a dose reduction (43% of those randomized to enalapril and 42% of those randomized to sacubitril/valsartan) had similar baseline characteristics and similar baseline predictors of the need for dose reduction.",2016-06-10,,introduction,3,1,0.0013033482702782557,randomized controlled trial,1.6,0.0020853572324452093,0.0020853572324452093,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.0013033482702782557, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020853572324452093, 'final_confidence': 0.0020853572324452093}"
med:pmid:27283779,med:pmid:27283779:sec:title:sent:0,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.,2016-06-10,,introduction,0,1,0.0013033482702782557,randomized controlled trial,1.6,0.0020853572324452093,0.0020853572324452093,"['vs', 'trial']","{""comparative_terms"": [""vs""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0013033482702782557, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020853572324452093, 'final_confidence': 0.0020853572324452093}"
med:pmid:27296397,med:pmid:27296397:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The 8442 patients randomized in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, in which sacubitril/valsartan (LCZ696) reduced both death and HF hospitalization more than enalapril, were a subset of 10 521 patients entering sequential, single-blind run-in periods (enalapril 10 mg twice daily for 2 weeks followed by LCZ696 200 mg twice daily for 4 to 6 weeks) to ensure short-term tolerability of the 2 study medications.",2016-06-01,,introduction,1,1,0.0012812616358373195,randomized controlled trial,1.6,0.0020500186173397113,0.0020500186173397113,"['tolerability', 'randomized', 'trial']","{""risk_terms"": [""tolerability""], ""study_context"": [""randomized"", ""trial""]}","['risk_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0012812616358373195, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0020500186173397113, 'final_confidence': 0.0020500186173397113}"
med:pmid:27207980,med:pmid:27207980:sec:abstract:sent:4,enalapril,ACEI,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,"After initial failures with neprilysin inhibition alone or dual neprilysin-angiotensin converting enzyme (ACE) inhibition, the Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) trial demonstrated that morbidity and mortality can be improved with the angiotensin receptor blocker neprilysin inhibitor sacubitril/valsartan (formerly LCZ696).",2016-05-20,,abstract,4,1,0.0012523939065447716,review,0.9,0.0011271545158902945,0.0011271545158902945,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0012523939065447716, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0011271545158902945, 'final_confidence': 0.0011271545158902945}"
med:pmid:27207980,med:pmid:27207980:sec:abstract:sent:5,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"In comparison to the ACE inhibitor enalapril, sacubitril/valsartan reduced the occurrence of the primary end point (cardiovascular death or hospitalisation for HF) by 20% with a 16% reduction in all-cause mortality.",2016-05-20,,abstract,5,1,0.0012523939065447716,review,0.9,0.0011271545158902945,0.0011271545158902945,[],,[],[],,,,[],,,,POS,2.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0012523939065447716, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0011271545158902945, 'final_confidence': 0.0011271545158902945}"
med:pmid:27207980,med:pmid:27207980:sec:abstract:sent:6,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,These findings suggest that sacubitril/valsartan should replace an ACE inhibitor or angiotensin receptor blocker as the foundation of treatment of symptomatic patients (NYHA II-IV) with HF and a reduced ejection fraction.,2016-05-20,,abstract,6,1,0.0012523939065447716,review,0.9,0.0011271545158902945,0.0011271545158902945,[],,[],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0012523939065447716, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0011271545158902945, 'final_confidence': 0.0011271545158902945}"
med:pmid:27170530,med:pmid:27170530:sec:conclusion:sent:7,enalapril,ACEI,sacubitril_valsartan,sacubitril/valsartan,Rates by ACEI/ARB pre-study dose stratification were 82.6% vs. 83.8% (P = 0.783) for high-dose/'condensed' vs. high-dose/'conservative' and 84.9% vs. 73.6% (P = 0.030) for low-dose/'conservative' vs. low-dose/'condensed'. Initiation/uptitration of sacubitril/valsartan from 50 to 200 mg twice daily over 3 or 6 weeks had a tolerability profile in line with other HF treatments.,2016-05-12,,conclusion,7,1,0.0012335110041978776,randomized controlled trial,1.6,0.001973617606716604,0.001973617606716604,"['vs', 'tolerability']","{""comparative_terms"": [""vs""], ""risk_terms"": [""tolerability""]}","['comparative_terms', 'risk_terms']",[],,,,[],safety,safety_acknowledgment,0.9,POS,1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0012335110041978776, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.001973617606716604, 'final_confidence': 0.001973617606716604}"
med:pmid:28785452,med:pmid:28785452:sec:abstract:sent:5,enalapril,enalapril,sacubitril_valsartan,ARNI,"The PARADIGM-HF study demonstrated robust superiority of ARNI compared with enalapril in patients with chronic symptomatic HFrEF, raising the question of whether ACEI should still have a role in the management of HFrEF.",2016-05-01,,abstract,5,1,0.001208011006701721,other,1.0,0.001208011006701721,0.001208011006701721,['compared with'],"{""comparative_terms"": [""compared with""]}",['comparative_terms'],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.681547+00:00,"{'recency_weight': 0.001208011006701721, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.001208011006701721, 'final_confidence': 0.001208011006701721}"
med:pmid:27143684,med:pmid:27143684:sec:conclusion:sent:6,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The benefit of sacubitril/valsartan over enalapril was similar to the primary outcome for the expanded composite (hazard ratio, 0.79; 95% confidence interval, 0.73-0.86) and was consistent across the components of the latter. Focusing only on HF hospitalizations underestimates the frequency of worsening and the serious implications of all manifestations of worsening.",2016-04-20,,conclusion,6,1,0.0011830381628913356,randomized controlled trial,1.6,0.001892861060626137,0.001892861060626137,"['similar to', 'serious']","{""comparative_terms"": [""similar to""], ""risk_terms"": [""serious""]}","['comparative_terms', 'risk_terms']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0011830381628913356, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.001892861060626137, 'final_confidence': 0.001892861060626137}"
med:pmid:27143684,med:pmid:27143684:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"We studied the frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Outpatient intensification of HF therapy was added to an expanded composite outcome with ED visits, HF hospitalizations, and cardiovascular deaths.",2016-04-20,,results,2,1,0.0011830381628913356,randomized controlled trial,1.6,0.001892861060626137,0.001892861060626137,"['add-on therapy', 'trial']","{""add-on therapy"": [""added to""], ""study_context"": [""trial""]}","['relationship:add-on therapy', 'study_context']",[],add_on,add_on,backbone,['add_on_to'],positioning,combination,0.85,NEG,-2.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0011830381628913356, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.001892861060626137, 'final_confidence': 0.001892861060626137}"
med:pmid:27143684,med:pmid:27143684:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,ARNI,Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).,2016-04-20,,results,0,1,0.0011830381628913356,randomized controlled trial,1.6,0.001892861060626137,0.001892861060626137,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEG,-3.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0011830381628913356, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.001892861060626137, 'final_confidence': 0.001892861060626137}"
med:pmid:27039128,med:pmid:27039128:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,ARNI,"The objective of this study was to determine the cost-effectiveness and cost per quality-adjusted life year (QALY) gained of sacubitril-valsartan relative to enalapril for treatment of heart failure with reduced ejection fraction (HFrEF).<h4>Background</h4>Compared with enalapril, combination angiotensin receptor-neprilysin inhibition (ARNI), as is found in sacubitril-valsartan, reduces cardiovascular death and heart failure hospitalization rates in patients with HFrEF.<h4>Methods</h4>Using a Markov model, costs, effects, and cost-effectiveness were estimated for sacubitril-valsartan and enalapril therapies for the treatment of HFrEF.",2016-03-30,,introduction,1,1,0.001136787319400601,other,1.0,0.001136787319400601,0.001136787319400601,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.001136787319400601, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.001136787319400601, 'final_confidence': 0.001136787319400601}"
med:pmid:27039128,med:pmid:27039128:sec:introduction:sent:3,enalapril,ACEI,sacubitril_valsartan,ARNI,Clinical probabilities were derived predominantly from PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).,2016-03-30,,introduction,3,1,0.001136787319400601,other,1.0,0.001136787319400601,0.001136787319400601,[],,[],[],,,,[],,,,,,,,"{'recency_weight': 0.001136787319400601, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.001136787319400601, 'final_confidence': 0.001136787319400601}"
med:pmid:26992459,med:pmid:26992459:sec:methods:sent:11,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"When compared to ACE inhibitor therapy in systolic heart failure patients, sacubitril/valsartan demonstrated reductions in all-cause mortality and hospitalization due to heart failure while maintaining a similar safety profile.<h4>What is new and conclusion</h4>A formulation that contains both sacubitril and valsartan was manufactured and approved by the FDA in July 2015 for the reduction of mortality and hospitalization in systolic heart failure patients.",2016-03-18,,methods,11,1,0.001111174698463729,review,0.9,0.001000057228617356,0.001000057228617356,"['compared to', 'delivery', 'safety', 'safety profile']","{""comparative_terms"": [""compared to""], ""delivery"": [""formulation""], ""risk_terms"": [""safety"", ""safety profile""]}","['comparative_terms', 'relationship:delivery', 'risk_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.001111174698463729, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.001000057228617356, 'final_confidence': 0.001000057228617356}"
med:pmid:26873495,med:pmid:26873495:sec:abstract:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure (composite primary endpoint) significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril.",2016-03-01,,abstract,2,1,0.0010758748830915934,review,0.9,0.0009682873947824341,0.0009682873947824341,"['double-blind', 'randomized', 'trial']","{""study_context"": [""double-blind"", ""randomized"", ""trial""], ""endpoint_terms"": [""primary endpoint""]}","['study_context', 'endpoint_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0009682873947824341, 'final_confidence': 0.0009682873947824341}"
med:pmid:26873495,med:pmid:26873495:sec:abstract:sent:3,enalapril,enalapril,sacubitril_valsartan,Sacubitril/valsartan,Sacubitril/valsartan was also superior to enalapril in reducing death from any cause and in limiting the progression of heart failure.,2016-03-01,,abstract,3,1,0.0010758748830915934,review,0.9,0.0009682873947824341,0.0009682873947824341,['superior'],"{""comparative_terms"": [""superior""]}",['comparative_terms'],[],alternative,disfavored,favored,['preferred_over'],,,,NEG,-1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0009682873947824341, 'final_confidence': 0.0009682873947824341}"
med:pmid:26873495,med:pmid:26873495:sec:abstract:sent:5,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,Symptomatic hypotension was significantly more common with sacubitril/valsartan than with enalapril; the incidence of angio-oedema was low.,2016-03-01,,abstract,5,1,0.0010758748830915934,review,0.9,0.0009682873947824341,0.0009682873947824341,[],,[],[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0009682873947824341, 'final_confidence': 0.0009682873947824341}"
med:pmid:26873495,med:pmid:26873495:sec:abstract:sent:6,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"Therefore, sacubitril/valsartan is a more effective replacement for an ACE inhibitor or an ARB in the treatment of HFrEF, and is likely to influence the basic approach to treatment.",2016-03-01,,abstract,6,1,0.0010758748830915934,review,0.9,0.0009682873947824341,0.0009682873947824341,[],,[],[],,,,[],,,,NEU,0.5,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0009682873947824341, 'final_confidence': 0.0009682873947824341}"
med:pmid:26915374,med:pmid:26915374:sec:introduction:sent:1,enalapril,enalapril,sacubitril_valsartan,angiotensin receptor neprilysin inhibitor,The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial.,2016-03-01,,introduction,1,1,0.0010758748830915934,randomized controlled trial,1.6,0.0017213998129465497,0.0017213998129465497,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""]}","['comparative_terms', 'study_context']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0017213998129465497, 'final_confidence': 0.0017213998129465497}"
med:pmid:26915374,med:pmid:26915374:sec:results:sent:2,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril. Eight thousand three hundred ninety-nine patients with New York Heart Association class II to IV HF with reduced EF [left ventricular EF (LVEF) ≤40%] were randomized to sacubitril/valsartan 97/103 mg twice daily versus enalapril 10 mg twice daily and followed for a median of 27 months.,2016-03-01,,results,2,1,0.0010758748830915934,randomized controlled trial,1.6,0.0017213998129465497,0.0017213998129465497,"['compared with', 'versus', 'randomized']","{""comparative_terms"": [""compared with"", ""versus""], ""study_context"": [""randomized""]}","['comparative_terms', 'study_context']",[],,,,[],comparative,comparative_efficacy,0.6,POS,1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0017213998129465497, 'final_confidence': 0.0017213998129465497}"
med:pmid:26915374,med:pmid:26915374:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,Sacubitril/Valsartan,Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.,2016-03-01,,results,0,1,0.0010758748830915934,randomized controlled trial,1.6,0.0017213998129465497,0.0017213998129465497,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0017213998129465497, 'final_confidence': 0.0017213998129465497}"
med:pmid:26976916,med:pmid:26976916:sec:abstract:sent:6,enalapril,ACEI,sacubitril_valsartan,ARNI,"In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.",2016-03-01,,abstract,6,1,0.0010758748830915934,review,0.9,0.0009682873947824341,0.0009682873947824341,"['compared with', 'trial']","{""comparative_terms"": [""compared with""], ""study_context"": [""trial""], ""endpoint_terms"": [""blood pressure""]}","['comparative_terms', 'study_context', 'endpoint_terms']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0010758748830915934, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0009682873947824341, 'final_confidence': 0.0009682873947824341}"
med:pmid:26873036,med:pmid:26873036:sec:abstract:sent:4,enalapril,ACE inhibitor,sacubitril_valsartan,sacubitril/valsartan,"PARADIGM-HF trial has proved the superiority of sacubitril/valsartan (LCZ696) over ACE inhibitor enalapril to reduce mortality and morbidity of symptomatic HF patients with reduced ejection fraction (HFrEF), setting the grounds for the replacement of ACE inhibitors by sacubitril/valsartan in the management of HFrEF.",2016-02-29,,abstract,4,1,0.00107383369953643,other,1.0,0.00107383369953643,0.00107383369953643,['trial'],"{""study_context"": [""trial""]}",['study_context'],[],,,,[],,,,POS,1.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.00107383369953643, 'study_type': 'other', 'study_type_weight': 1.0, 'mention_count': 1, 'combined_weight': 0.00107383369953643, 'final_confidence': 0.00107383369953643}"
med:pmid:26637405,med:pmid:26637405:sec:abstract:sent:5,enalapril,ACE inhibitor,sacubitril_valsartan,ARNI,"In the present review, we have summarized the current knowledge on the NP system, focusing on its role in HF and we provide an overview of the pharmacological attempts to modulate NP in HF: from the negative results of the study with neprilysin (NEP) inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors, to the most recently and extremely encouraging results obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI (Ang receptor NEP inhibitor).",2016-01-01,,abstract,5,1,0.0009600136009542968,review,0.9,0.0008640122408588671,0.0008640122408588671,['review'],"{""study_context"": [""review""], ""claim_strength_terms"": {""exploratory"": [""encouraging""]}}","['study_context', 'claim_strength:exploratory']",[],,,,[],,,,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0009600136009542968, 'study_type': 'review', 'study_type_weight': 0.9, 'mention_count': 1, 'combined_weight': 0.0008640122408588671, 'final_confidence': 0.0008640122408588671}"
med:pmid:26754626,med:pmid:26754626:sec:conclusion:sent:7,enalapril,enalapril,sacubitril_valsartan,sacubitril/valsartan,"The benefit of LCZ696 (sacubitril/valsartan) compared with enalapril was consistent across the range of HbA1c in the trial. In patients with heart failure and reduced ejection fraction, dysglycemia is common and pre-diabetes mellitus is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no diabetes mellitus and HbA1c < 6.0%).",2016-01-01,,conclusion,7,1,0.0009600136009542968,randomized controlled trial,1.6,0.0015360217615268748,0.0015360217615268748,"['compared with', 'risk', 'trial']","{""comparative_terms"": [""compared with""], ""risk_terms"": [""risk""], ""study_context"": [""trial""], ""endpoint_terms"": [""hba1c""], ""risk_posture_terms"": {""acknowledgment"": [""higher risk"", ""risk of""]}}","['comparative_terms', 'risk_terms', 'study_context', 'endpoint_terms', 'risk_posture:acknowledgment']",[],,,,[],comparative,comparative_efficacy,0.6,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0009600136009542968, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0015360217615268748, 'final_confidence': 0.0015360217615268748}"
med:pmid:26754626,med:pmid:26754626:sec:results:sent:2,enalapril,ACEI,sacubitril_valsartan,ARNI,"We investigated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We examined clinical outcomes in 8399 patients with heart failure and reduced ejection fraction according to history of diabetes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4% [42-47 mmol/mol; pre-diabetes mellitus], and ≥ 6.5% [≥ 48 mmol/mol; diabetes mellitus]), in Cox regression models adjusted for known predictors of poor outcome.",2016-01-01,,results,2,1,0.0009600136009542968,randomized controlled trial,1.6,0.0015360217615268748,0.0015360217615268748,['trial'],"{""study_context"": [""trial""], ""endpoint_terms"": [""a1c"", ""hba1c""]}","['study_context', 'endpoint_terms']",[],,,,[],evidence,clinical_trial,0.49999999999999994,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0009600136009542968, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0015360217615268748, 'final_confidence': 0.0015360217615268748}"
med:pmid:26754626,med:pmid:26754626:sec:title:sent:0,enalapril,ACEI,sacubitril_valsartan,ARNI,Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.,2016-01-01,,results,0,1,0.0009600136009542968,randomized controlled trial,1.6,0.0015360217615268748,0.0015360217615268748,"['risk', 'trial']","{""risk_terms"": [""risk""], ""study_context"": [""trial""]}","['risk_terms', 'study_context']",[],,,,[],evidence,clinical_trial,0.7,NEU,0.0,lexicon_v1,2026-01-08T12:24:15.665444+00:00,"{'recency_weight': 0.0009600136009542968, 'study_type': 'randomized controlled trial', 'study_type_weight': 1.6, 'mention_count': 1, 'combined_weight': 0.0015360217615268748, 'final_confidence': 0.0015360217615268748}"
